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Short history of antimicrobial therapy 
 
The first antibacterial chemotherapy that revolutionised the treatment of 
bacterial infections was the sulphonamide Prontosil, discovered in 1932 and 
introduced in approximately 1935 [1-3]. The sulfonamides are synthetic 
antimicrobial agents developed in the German dye industry by Gerhard Domagk. He 
continued the work of Paul Ehrlich, who discovered arsphenamine (Salvarsan) in 
1910, the “magic bullet” or “magische Kugel” for the treatment of syphilis [4]. 
Salvarsan is a chemical derivative of the toxic drug Atoxyl, which was used for the 
treatment of trypanosomiasis [5]. Much earlier than Salvarsan and Atoxyl, quinine 
was isolated from the cinchona bark in 1820 in Paris by Caventou and Pelletier [6, 
7]. This bark was also known as pulvus indicus or Jezuits bark as a remedy for 
malaria, published by Herman van der Heyden in 1643 [8]. The first antibiotic was 
penicillin, discovered by Alexander Fleming in 1928, purified by Chain and Florey 
and introduced in approximately 1941 [2, 9].  Streptomycin was the first 
aminoglycoside discovered by Waksman and Schatz in 1943 and introduced in 1946 
[10, 11]. Waksman suggested to use the term antibiotic for a chemical substance 
produced by a micro-organism which has the capacity to inhibit the growth of and 
even to destroy bacteria and other micro-organisms [12]. Since then many 
antibiotics followed during the golden age of antibiotic discoveries. The 
approximate time line of the discoveries (and introductions) of the major 
antimicrobial classes, after sulphonamides and β-lactam antibiotics, is as follows: 
chloramphenicol discovery in 1946 (introduction in 1948), macrolide in 1948 
(1951), tetracycline in 1944 (1952), glycopeptide in 1953 (1958), rifamycin in 1957 
(1958), and quinolone (synthetic) in 1961 (1968) [2]. After this golden age, only few 
new antibiotics have been added: oxazolidinone (synthetic) in 1955 (2000) and 
lipopeptides in 1986 (2003) [2]. Resistance against antimicrobials was observed 
shortly after each antimicrobial discovery [2]. The antimicrobial use steadily 
increased with the discovery of all these antimicrobial drugs, and is still increasing 
[13]. A clear relationship has been found between the percentage of resistant strains 
and antimicrobial use. The selection of resistance was strongly associated with prior 
antimicrobial treatment and importantly suboptimal antimicrobial exposure. On the 
other hand, dosing regimens that result in high antimicrobial concentrations may 
lead to adverse events. Increasing antimicrobial resistance is a worldwide problem 
and antimicrobial stewardship programs are being developed to ensure that 
antimicrobial therapy is used correctly in all groups of patients. Elderly patients 
should be a specific target group for more in depth studies to improve the 
antimicrobial therapy, since the therapeutic width may be narrow due to 
pharmacokinetic changes associated with ageing. 
 
  
The elderly patient 
 
Classification 
Ageing is a gradual process with interindividual variance. Any cut off for 
elderly patients can be criticised. A cut-off >65-70 years for elderly patients and a 
cut-off >80-85 years for the very elderly patients are generally used. A cut off 
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depends on many factors, such as time and geography. E.g. in 1900 only 6% of the 
population in the Netherlands was older than 65 years [14]. The number of elderly 
people is rapidly growing in the Western world. Eurostat predicts that the percentage 
of elderly people (>65 years) in the 27 countries of the European Union will rise 
from 17% in 2011 to 30% in 2060 and the very elderly people (>80 years) from 5% 
to 12% [15].  In other parts of the world, such as Africa, the life expectancy is much 
lower. The World Health Organisation suggest a cut-off of 60 years for elderly 
patients in Africa, while others think a cut-off of 50 or 55 years would be more 
reasonable in Africa [16]. In parts of Sardinia and Sicily a strikingly high number of 
centenarians live, which lead to several research questions and could lead to a higher 
cut-off for elderly people in Sardinia and Sicily [17, 18].    
 
Infections and antimicrobial use in elderly patients 
Elderly patients have more co-morbidities, especially cardiovascular 
disease, neurological disease and diabetes, which influences host defence 
mechanisms [19].  Physiologic functions, such as cough reflex and wound healing 
are diminished in elderly patients [20, 21]. The innate, cellular and humeral 
immunity is decreasing in elderly patients without compelling evidence that this has 
direct clinical relevance [22]. Elderly people experience more infections with longer 
length of hospital stay and higher mortality rates [23]. For example, 50% of the 
patients with a pneumonia are older than 65 years and 90% of the mortality due to 
pneumonia are in patients older than 65 years [24]. Other common infections in 
elderly patients are, urinary tract infections and skin infections [23, 24]. Only a few 
studies have shown higher antimicrobial consumption in elderly patients [25-27]. 
Taken together, the elderly people are a large and growing population with a high 
number of infections and a high use of antimicrobial therapy. 
 
 
Overview of pharmacokinetic changes with ageing 
 
Higher age is characterised by a decrease in functional capacity of most organs, 
leading to changes in absorption, distribution and protein binding [28]. Several 
reviews on antimicrobial therapy in elderly patients discuss the knowledge of 
pharmacokinetic changes that influence antimicrobial blood concentrations [29-36]. 
In Table 1 the different antimicrobial classes are shown with regard to the most 
important antimicrobial pharmacokinetic characteristics that influence antimicrobial 
blood concentrations in elderly patients, i.e. clearance and hydrophilic or lipophilic 
nature of the antimicrobial drugs. 
 
 
Absorption 
Although, elderly people have decreased acid production and delayed gastric 
emptying the total drug absorption seems similar to that of younger patients [28, 33, 
35, 55, 56].  
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Table 1. Important pharmacokinetic characteristics of antimicrobial drug classes important in elderly 
patients. 
Clearance (CL) Hydrophilic Lipophilic 
Renal CL (%) Aminoglycosides (90-95%) [37] Quinolones (40-93%) [38] 
 Penicillines (60-80%) [39-41] Sulphonamides 
 Cefalosporins Trimethoprim (60-80%) [42] 
 Carbapenems (70-80%) [43-45]  
 Glycopeptides (80-90%) [46]  
 Lipopeptides (50%) [47]  
Metabolic CL (%)  Macrolides (90%) [48] 
  Rifamycins (60-95%)[49-51] 
  Clindamycin (80-90%) [52] 
  Tetracyclines (60%)[53] 
  Oxazolidinones (60-70%) [54] 
Sulphonamides 
 
  
Distribution 
The volume of distribution (Vd) of antimicrobial drugs is altered in elderly 
patients. With ageing the total body water from intra- and extracellular spaces 
decreases with 10-15% [28]. This leads to a decrease of Vd hydrophilic drugs, which 
will increase the blood concentrations of hydrophilic drugs [57]. In men body fat 
increases from 18% to 36% and in women body fat increases from 33% to 45% with 
ageing [28, 58]. This leads to an increase in Vd of lipophilic drugs, which will 
decrease the blood concentrations of lipid soluble drugs in elderly patients [59]. The 
decrease of blood concentrations of lipophilic drugs could be less pronounced, 
because of the already large Vd of most lipophilic drugs. Furthermore, frail elderly 
patients have lost their fat tissue again and consequently have lost their increase in 
Vd of lipid soluble drugs [60].  
In conclusion, the Vd of hydrophilic drugs will decrease resulting in increased 
concentrations of hydrophilic antimicrobial drugs and the Vd of lipophilic drugs will 
increase, which will lead to lower concentrations of lipophilic antimicrobial drugs in 
elderly patients.  
 
Renal elimination 
Renal function is steadily decreasing with ageing. Reduced renal function leads 
to a longer half-life (T½), higher antimicrobial blood concentrations and area under 
the curve (AUC). However, serum creatinine remains stable in elderly patients, 
because lean muscle mass also decreases [28]. Malmrose et al. showed the 
predictive accuracy of different estimated creatinine clearance (CLcr) ranges from 
18-38 mL/min in 762 high functioning community-dwelling elderly patients. 
Malmrose et al. advises to estimate CLcr only when urine specimens are impractical 
or when serum drug concentrations are not available [61]. Lindeman et al. showed a 
high interindividual decline in glomular filtration rate with ageing [62]. This 
variability of  interindividual decline in glomular filtration rate and in the range of 
muscularity in elderly patients, make estimations of CLcr inaccurate in elderly 
patients [61]. For an elderly person, the only way to be certain about his or her renal 
function is to measure it with a  24-hour measurement of creatinine in urine [22]. 
However, this is often impractical.  
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In conclusion, blood concentrations of renally cleared antimicrobial drugs are 
increased in elderly patients, due to a decreased kidney function. However, careful 
interpretation of estimated CLcr in elderly patients remains necessary. 
 
Metabolism 
The effect of age on liver function is less clear. Although, the volume of the 
liver and portal flow decreases with age, the liver function and cytochrome P450 
(CYP) seem to remain fairly stable with ageing [28, 63]. On the other hand, the 
chance of drug-drug interaction increases with high rates of polypharmacy in elderly 
patients [29, 30, 32].  
 
Protein binding 
The free antimicrobial drug is active, antimicrobial drugs bound to proteins 
cannot act against microorganisms and are inactive. A decrease in serum albumin 
will decrease the protein bound drug fraction (inactive) and increase the free drug 
(active) in plasma. This may influence the distribution and clearance of highly 
protein bound antimicrobial drugs, but may not be clinically relevant [32].  
 
Conclusions 
The decrease in renal function and Vd of hydrophilic drugs seem to be the 
most important antimicrobial pharmacokinetic characteristics that influence 
antimicrobial blood concentrations in elderly patients. Therefore, the highest blood 
concentrations in elderly patients are expected with hydrophilic antimicrobial drugs 
that are renally cleared. The change in blood concentrations of lipophilic 
antimicrobial drugs that are renally cleared are likely to increase, but could decrease 
in individual elderly patients and the blood concentrations of lipophilic antimicrobial 
drugs that are metabolically cleared are expected to decrease. The pharmacokinetic 
studies in elderly patients are not conclusive and reviews on pharmacokinetic 
antimicrobial studies in elderly patients are scarce. With increasing numbers of 
elderly patients, accurate dosing advices for this age group is necessary. More 
pharmacokinetic studies in elderly patients and a new review on pharmacokinetic 
studies seems warranted. 
 
 
Antimicrobial pharmacokinetic studies in elderly patients 
 
Antimicrobial drugs in elderly patients are often dosed in the same manner 
as in young adult patients. On the other side of the age spectrum, neonates and 
young children also have more infections, and it has been shown that different 
antimicrobial dosing schedules are necessary in neonates and young children [64]. It 
is not clear why such adjustments in antimicrobial regimens have not been made for 
elderly patients in which risks for underdosing and overdosing of medication are 
readily available. To prevent overdosing, the aphorism “Start low, go slow” should 
be used for dosing medication in elderly patients, but this aphorism seems to be 
harmful for antimicrobial treatment. For antimicrobial therapy, Paul Ehrlich already 
advised in 1913 “Frapper fort et frapper vite”, hit them hard and hit them fast [65]. 
This adagium is based on the thought that suboptimal antimicrobial blood 
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concentrations will induce antimicrobial resistance and treatment failure. However, 
by avoiding underdosing of antimicrobial therapy in elderly patients, the risk of too 
high blood concentrations resulting in adverse drug events (ADE) and higher 
morbidity and mortality increases. The advice of Paul Ehrlich still is applied in 
antimicrobial therapy, but in elderly patients altered pharmacokinetics as a result of 
physiologic changes of ageing need to be taken into account. Antimicrobial 
regimens for adults in general may not be directly extrapolated to the elderly.  
Only a limited number of pharmacokinetic studies in elderly patients have been 
reported. Ljungberg et al. and Meyers et al. have reviewed pharmacokinetic studies 
in elderly volunteers and elderly patients, in 1987 and in 1989, respectively [56, 66]. 
The first review of Ljungberg et al. included the first studies in elderly patients, 
from 1950s to 1987. The second review of Meyers et al. covered a short period of 
antibiotic pharmacokinetic studies from 1987-1989 [66]. Since 1989, several new 
antibiotics have been developed and new studies in elderly patients have been 
described. Furthermore, the methods for measuring blood concentrations of 
antibiotics have improved. For instance, agar disk diffusion bioassays are not used 
anymore, as this method is time consuming and the zone of inhibition is influenced 
by several variables [31]. High performance liquid chromatography (HPLC) is now 
most often used to determine concentrations of antimicrobial therapy, such as β-
lactam antibiotics, quinolones and macrolides. For aminoglycosides and 
glycopeptides, fluorescence polarization immunoassays (FPIA) are used nowadays.  
To determine the optimal dosing regimens for elderly patients, pharmacokinetic 
studies of antimicrobial drugs were reviewed.  
 
Selection of pharmacokinetic studies of antimicrobial therapy in elderly people 
English written studies were included that used comparable analytical 
methods, i.e. immunoassays for aminoglycosides and glycopeptides studies and 
HPLC for the other antimicrobial drugs. The bioassay studies were excluded. The 
US Food and Drug Administration (FDA) describes requirements  for accuracy, 
precision, selectivity, sensitivity, reproducibility and stability in the Guidance for 
Industry Bioanalytical Method Validation [67]. At least an acceptable intra- and 
interbatch precision coefficient of variation (CV) must be within 15%. Information 
on pharmacokinetic parameter calculations and pharmacokinetic program must be 
included. The study population should be well defined and elderly subjects (>65 
years) should be compared with younger subjects, see Table 2. 
 
 
Table 2. Selection criteria. 
1. English written 
2. Methods: Immunoassays (gentamicin and vancomycin)/HPLC (other antimicrobial drugs) 
3. Acceptable intra- and interbatch precision coefficient of variation (CV) 
4. Comparison elderly group versus younger group 
 
 
Publications were retrieved by a computerised search of MEDLINE (1966-
2014). In the first stage of the search strategy Medical Subject Headings (MeSH) 
were used; aged (elderly) and pharmacokinetics. This strategy was combined with 
antibacterial therapy as a whole MeSH term: Anti-Bacterial agents and most 
commonly used single antibacterial therapy, i.e. MeSH terms: penicillin, 
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flucloxacillin, amoxicillin, amoxicillin-potassium clavulanate combination, 
piperacillin, piperacillin tazobactam combination product, cefazolin, cefuroxime, 
ceftriaxone, ceftazidime, cefotaxime, cefepime, meropenem, doripenem, ertapenem, 
imipenem, aztreonam, gentamicin, tobramycin, amikacin, vancomycin, teicoplanin, 
daptomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, 
linezolid, clindamycin, trimethoprim, metronidazole, ciprofloxacin, levofloxacin, 
moxifloxacin and rifampin. Only English studies were selected by activating 
language filter in MEDLINE: English.  
 
Results of pharmacokinetic studies of antimicrobial therapy in elderly people 
The search strategy resulted in 1353 publications, 1306 were excluded, 
because they were not pharmacokinetic studies in elderly patients. Twenty three 
studies did not meet the selection criteria. In total 24 studies were included, Figure 1. 
These 24 pharmacokinetic studies in elderly volunteers (n=15) and elderly patients 
(n=9) are summarised in Table 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Search strategy and article selection. 
 
 
Aminoglycosides  
Aminoglycosides are the most hydrophilic of all antibiotics. 
Aminoglycosides distribute in the vascular space and the interstitial space of most 
tissues [68]. Aminoglycosides do not penetrate human biological membranes and are 
lipid insoluble. The extracellular water is decreased in elderly patients, which should 
lead to lower Vd and higher serum or plasma concentrations of aminoglycosides. 
However, Bauer et al. found lower Vd of gentamicin, but higher Vd of amikacin in 
younger patients compared to elderly patients [69, 70]. The Vd of tobramycin was 
equal in younger and elderly patients. The Vd of aminoglycosides is not consistently 
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changed in these studies. Therefore, it is not possible to adjust aminoglycosides 
dosing according to changes in Vd with ageing. 
Aminoglycosides are almost completely renally cleared. Only slightly 
decreased aminoglycoside clearance was found in the age group of 60-79 years 
compared to the age group of 20-39 years [69, 70]. However, with renal function 
steadily decreasing with ageing and small therapeutic range of the aminoglycosides, 
caution with aminoglycoside dosing in elderly patients seems warranted. In elderly 
patients monitoring of CLcr, therapeutic drug monitoring (TDM) and short courses 
(<3 days) of aminoglycosides are to be advised to prevent high blood concentrations 
and prevent ADEs, such as nephrotoxicity [71, 72].  
 
β-lactam antibiotics 
β-lactam antibiotics are hydrophilic and are well distributed in most tissues. 
β-lactam antibiotics are relatively insoluble in lipid and penetrate cells poorly. Most 
β-lactam antibiotics are rapidly excreted into the urine and have short T½ (30-70 
min). Exceptions are ceftriaxone and cefoperazone which are excreted both renally 
and by biliary route.  
Penicillins. Sjoval et al. found higher Vd of amoxicillin and ampicillin in 
elderly volunteers, while Rho et al. found lower Vd in elderly volunteers, Table 3. 
Sjoval et al. did not find a difference in total amoxicillin clearance, while Rho et al. 
did find a decreased total amoxicillin clearance in elderly volunteers. A decreased 
renal clearance in elderly patients leads to higher blood concentrations in elderly 
patients [73, 74]. However, the broad therapeutic window of amoxicillin makes dose 
adjustments usually not necessary in elderly patients. 
Cephalosporins. Studies of ceftazidime in elderly patients are conflicting. Some 
studies showed decreased Vd and decreased clearance of ceftazidime in elderly 
patients, although dosage adjustments in healthy elderly adults were not deemed 
necessary [75, 76]. No difference in Vd and a slightly decreased clearance was 
found for ceftriaxone and cefepime in elderly compared to younger subjects without 
the need for dose adjustments [77, 78]. In other studies higher Vd in elderly patients, 
reduced clearance of ceftazidime and increased AUC were reported and it was 
advised to lower the ceftazidime dose in elderly patients [79]. For cefotaxime, a 
decreased clearance in patients >80 years compared to 60-80 years was found, 
leading to the advice to decrease the dose in >80 years [80].  
Carbapenems. Ljungberg et al. suggest to consider dose adjustments for 
meropenem, due to a reduced renal clearance of meropenem and its metabolite (ICI 
213,689) and a possible decreased capacity to metabolize meropenem [81]. Vd of 
meropenem was not different between younger and elderly patients. The clearance 
of ertapenem was slightly decreased in elderly patients, but did not accumulate in 
elderly volunteers. Dose adjustments were not necessary for elderly patients [82].  
Monobactams. Meyers et al. found higher aztreonam blood concentrations in 
elderly patients, due to decreased renal clearance [83]. The Vd of aztreonam was 
increased in elderly patients. Meyers et al. suggested altered dosages for elderly 
patients should be considered, because of an increased AUC.  
Conclusion of β-lactam antibiotic studies in elderly patients. Only few β-lactam 
antibiotics have been studied in elderly subjects in comparison with younger 
subjects. Advices on dosing β-lactam antibiotics are inconsistent, due to inconsistent 
changes in Vd and renal clearance. Studies with FDA approved requirements for 
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bioanalytical method validation and investigating elderly (>70 years) and very 
elderly patients (>80 years) might show pharmacokinetic age associated differences.    
 
Glycopeptides 
 Vancomycin is hydrophilic and diffuses well into epithelial lining fluid and 
reached   good concentrations in kidney, liver, heart, lung and abscesses in a post 
mortem study [84]. Elderly patients had reduced clearance of vancomycin and an 
increased Vd. Age was an independent predictor of T½, Vd and clearance in the 
multivariable analysis [85-87]. Elderly patients required smaller daily dose than 
younger patients, 18 (±6) vs 25 (±8) mg/kg [85]. A population pharmacokinetic 
study of adult and elderly patients with normal serum creatinine showed lower 
vancomycin clearance and lower Vd in elderly patients [88]. Inconsistent changes of 
Vd, decreased clearance of vancomycin and small therapeutic window make TDM 
and CLcr monitoring necessary in elderly patients. Studies with FPIA with selective 
monoclonal antibodies and FDA approved requirements for bioanalytical method 
validation and investigating elderly (>70 years) and very elderly patients (>80 years) 
might show pharmacokinetic age associated differences (i.e. Vd and vancomycin 
clearance).   
 
Lipopeptide (Daptomycin) 
Dvorchik et al. compared daptomycin pharmacokinetic in a group of young 
adult and elderly volunteers [89]. No significant differences in peak concentration 
(Cmax) and Vd were seen. Elderly volunteers had higher AUC (58%), due to lower 
clearance of daptomycin. Therefore, lower dosage should be considered in elderly 
patients.  
 
Quinolones 
Ljungberg et al. found higher ciprofloxacin blood concentrations and AUC 
in elderly volunteers, due to a decreased ciprofloxacin clearance. Distribution was 
unaffected in elderly volunteers, but dose reductions should be considered [90]. The 
AUC of levofloxacin [91] and moxifloxacin [92] also increased in elderly patients, 
due to a reduced clearance of the quinolone. However, dose reductions were not 
advised by these authors. A fluoroquinolone Monte Carlo simulation based on 1000 
simulated elderly patients with reduced CLcr of published pharmacokinetic and 
pharmacodynamic data showed that suggested dose reductions in elderly patients did 
not allow the same AUCs compared to normal dose in patients with normal CLcr. 
Reducing ciprofloxacin dose from 500 mg to 250 mg twice daily with CLcr 30-60 
mL/min and reducing levofloxacin from 500 mg to 250 mg once daily with CLcr 20-
50 mL/min levofloxacin lead to too low AUCs [93]. The estimated CLcr might not 
be accurate enough in elderly patients [61]. More in depth studies are necessary in 
elderly patients to improve dosing strategies of quinolones in elderly patients with 
CLcr reductions.  
 
Macrolides 
No difference in Vd of clarithromycin is seen in elderly volunteers, whereas 
the AUC is almost doubled, probably due to a decrease in renal clearance [94]. The 
differences in metabolite pharmacokinetic parameters were small [94]. 
Clarithromycin has a higher renal clearance (20-40%), compared to azithromycin 
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and erythromycin (5-12%) [95]. Dose adjustments in elderly patients are usually not 
necessary. Closer clinical monitoring for ADE has been advised [45,46].  
 
Tetracyclines 
Tetracyclines are well distributed in most tissues. No significant differences 
were found in pharmacokinetic parameters of tigecycline in elderly volunteers, 
although elderly patients seemed to have lower clearance and lower Vd [96]. Blood 
concentrations were higher in elderly patients, but dose adjustments are not 
recommended as no ADEs were noticed. 
  
Oxazolidinones 
No differences were noted in AUC, Cmax, non-renal clearance and T½ 
between young and elderly volunteers [97]. In a Japanese population model, it was 
shown that bodyweight and age were influential covariates for linezolid clearance 
and elderly patients had lower linezolid clearance [98]. The difference might be 
explained by the difference in body weight. In the study of Sisson et al. the weight 
of the elderly patients was 10% higher than the younger patients. The effect of age 
might be blinded by the effect of higher bodyweight of the elderly patients.   
 
Nitro-imidazols 
No difference were found in elderly patients and young controls in blood 
concentrations, Vd en clearance of metronidazole [99]. 
 
 
Conclusion 
This review shows the difficulty in interpretation of pharmacokinetic 
studies of antimicrobial therapy in elderly patients. Many pharmacokinetic studies 
have been done 20-40 years ago with different methods for determining drug 
concentrations. Since 1989, a few studies have been added, mainly on new 
antimicrobial agents. This gap in pharmacokinetic studies in elderly patients is 
striking. Pharmacokinetic studies in elderly patients are difficult to interpret, because 
the use of co-medication and co-morbidity. Ideally, methods used for measuring 
blood concentrations should be within FDA approved requirements and dosing 
studies should be done in well-defined age groups in both healthy elderly volunteers 
and in infected elderly patients. Young controls should be included in the studies. 
However, only limited pharmacokinetic studies are done in elderly patients and no 
antimicrobial drug is studied in an ideal setting. Furthermore, many old studies were 
not completely validated within FDA approved requirements for accuracy, precision, 
selectivity, sensitivity, reproducibility and stability [67]. The high interindividual 
variance of ageing further complicates exact dosing advices of antimicrobial drugs 
in elderly patients. Ageing is a gradual process where differences in 
pharmacokinetic changes with younger population become gradually visible. Most 
likely the largest differences can be found in the very elderly patients at the end of 
the age spectrum. Little advice about optimal dosing regimens is available for 
elderly patients.  
The pharmacokinetic studies show that most antimicrobial blood 
concentrations are different in elderly patients. The decline in kidney function is the 
most important and consistent pharmacokinetic change in elderly patients [73, 75-
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87, 89]. However, a few studies did not find differences in antimicrobial clearance 
[69, 70, 74]. Despite changes in body composition in elderly patients [61], the Vd of 
hydrophilic and lipophilic antimicrobial drugs do no change consistently and do not 
seem to have a substantial impact on antimicrobial blood concentrations, Table 3. 
However, the Vd is also affected by other factors, such as, obesity, sepsis, fever, 
fluid infusions, hypalbuminemia and protein binding. Furthermore, this age 
associated changes might be more clearly visible at the end of the age spectrum. 
Dose adjustments are usually not necessary in metabolic cleared antimicrobial drugs 
[94, 95, 97, 98].   
Elderly patients need more accurate dosing strategies. Therefore, 
pharmacokinetic studies should not only be done in healthy volunteers, but also in 
real life hospitalised elderly patients. FDA approved requirements for bioanalytical 
methods should be used to determine the influences of pharmacokinetic parameters 
(i.e. renal clearance and Vd) on antimicrobial blood levels when ageing. Elderly 
patients should be investigated at the end of the age spectrum and/or in specific 
elderly patient groups, such as frail elderly patients. Additionally, more accurate 
measurement of kidney function should be studied in pharmacokinetic studies.   
 
 
Aim of this thesis 
 
The aim of this thesis is to optimise dosing strategies in elderly people. 
Therefore, antimicrobial use and pharmacokinetic parameters of renally cleared  
hydrophilic (amoxicillin and vancomycin) and renally cleared lipophilic 
antimicrobial drugs (ciprofloxacin) were evaluated in hospitalised adult patients. 
Elderly (>70 years) and very elderly (>80 years) patients are compared to younger 
patients 
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Outline of thesis 
 
As discussed in the previous section, elderly patients consume more 
antimicrobial drugs and are more at risk for ADE and underdosing. Antimicrobial 
pharmacokinetics in elderly patients is different compared to younger patients due to 
physiologic changes of ageing. For safe and effective antimicrobial therapy in 
elderly patients, both knowledge of infections, antimicrobial consumption and 
pharmacokinetics are necessary. The backbone of this thesis is antimicrobial therapy 
in elderly patients. However, other research questions were investigated as well.  
Elderly patients will use more antimicrobial therapy compared to younger 
patients. The majority of antimicrobial therapy (>80%) is prescribed in Primary 
Care. In chapter 2 the antimicrobial prescriptions of elderly patients in general 
practice is investigated over a 10-year period. Additionally, adverse drug events of 
antimicrobials were investigated in relation to age. Elderly patients have changed 
pharmacokinetics due to ageing. The dosing of antimicrobial drugs in elderly 
patients should not be extrapolated from younger patients. In chapter 3 a high 
performance liquid chromatography method to measure ciprofloxacin blood levels is 
developed and validated by FDA required standards for accuracy, precision, 
selectivity, sensitivity, reproducibility and stability [67]. This method is used in 
chapter 4 to investigate the pharmacokinetics of ciprofloxacin intravenously in 
hospitalised patients. Elderly patients (>70 years and >80 years) are compared to 
younger patients. In chapter 5 amoxicillin-clavulanic acid intravenously is 
investigated in hospitalised patients. In chapter 6 and 7 vancomycin intravenously 
is investigated with FPIA with monoclonal antibodies in hospitalised patients. FPIA 
with monoclonal antibodies are considered as the method of choice in renal failure, 
and consequently in elderly patients. Immunoassays with polyclonal antibodies can 
overestimate the active vancomycin concentration, by detection of  accumulating 
vancomycin degradation products [100, 101]. Again elderly patients are compared to 
younger patients. Chapter 6 focuses more on the vancomycin dosing of neutropenic 
patients. In chapter 7 different methods to estimate the creatinine clearance and 
different methods to estimate the vancomycin clearance are investigated. Chapter 8 
compromises the general discussion and future perspectives. 
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Abstract 
 
Introduction. Antibiotic consumption is associated with adverse drug events (ADE) 
and increasing antibiotic resistance. Detailed information of antibiotic prescribing in 
different age categories is scarce, but necessary to develop strategies for prudent 
antibiotic use. The aim of this study was to determine the antibiotic prescriptions of 
different antibiotic classes in general practice in relation to age.  
Methods. Retrospective study of 22 rural and urban general practices from the 
Dutch Registration Network Family Practices (RNH). Antibiotic prescribing data 
were extracted from the RNH database from 2000-2009. Trends over time in 
antibiotic prescriptions were assessed with multivariate logistic regression including 
interaction terms with age. Registered ADEs as a result of antibiotic prescriptions 
were also analyzed. 
Results. In total 658,940 patients years were analyzed. In 11.5% (n=75,796) of the 
patient years at least one antibiotic was prescribed. Antibiotic prescriptions 
increased for all age categories during 2000-2009, but the increase in elderly patients 
(>80 years) was most prominent. In 2000 9% of the patients >80 years was 
prescribed at least one antibiotic, which increased to 22% in 2009 (P<0.001). 
Elderly patients had more ADEs with antibiotics and co-medication was identified 
as the only independent determinant for ADEs. 
Conclusion/Discussion. The rate of antibiotic prescribing for patients who made a 
visit to the GP is increasing in the Netherlands with the most evident increase in the 
elderly patients.  This may lead to more ADEs, which might lead to higher 
consumption of health care and more antibiotic resistance. 
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Introduction 
 
The majority of antibiotics (80%) in the Netherlands are prescribed in 
primary care [1]. Outpatient antibiotic consumption is higher in elderly patients than 
in the general population [2-4] and most antibiotics are prescribed in elderly patients 
for respiratory tract infections (RTI) [5], skin and soft tissue infections [6]
 
and 
urinary tract infections (UTI) [7]. However, detailed information of antibiotic 
prescribing in elderly is scarce. The majority of studies have been done in children, 
who also have a high antibiotic consumption [2, 8, 9]. The paucity of data on 
antibiotic use in elderly is surprising since elderly patients are more susceptible to 
toxic effects of antibiotics. For instance, adverse drug events (ADEs) have been 
described more frequently in frail elderly with co-morbidity and co-medication [10]. 
Additionally, elderly patients have altered pharmacokinetics, such as decreased 
absorption and elimination, which alters antibiotic blood levels, thereby influencing 
the risk of ADEs [11].  
Antibiotic use is slowly, but steadily increasing in the Netherlands since 
2005 [12]. It is unknown whether the increase in antibiotic use is equal in all age 
categories. Trends over time in antibiotic use per age category have not been studied 
and more information on the highest age categories is crucial as a quarter of the 
Dutch population will be above 65 years in the near future, similar to other European 
countries [13].   
To determine trends in antibiotic prescribing in elderly, we have assessed 
antibiotic prescription rates by age categories in general practices over a ten year 
period in a large general practice database. Additionally, we have analyzed the 
incidence of registered ADEs due to antibiotics. 
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Methods 
 
The data for this study are obtained retrospectively from the Dutch 
Registratie Netwerk Huisartsen (RNH, Registration Network Family Practices). The 
study group is described and regrouped into four different age categories: 18-44 
years, 45-64 years, 65-79 years and ≥80 years. In these age categories, we have 
compared rates and trends over time in antibiotic prescriptions. Individual 
prescriptions per patient in a year were used as measure of prescriptions. For each 
prescription (at the moment of the specific consultation) information on ADE (until 
4 weeks after prescription) and co-medication (at and during the prescription) were 
used. Data were then aggregated over a specific patient and calendar year to obtain a 
meaningful measure (% per patient-year). 
 
Data source 
The RNH is a continuous, computerized and anonymous database from 22 
rural and urban general practices in the south of the Netherlands, Limburg, [14]. 
During the study period the average number of patients >18 years in the RNH was 
65,894 patients. The population was stable with respect to general sociodemographic 
characteristics.  
The GP is responsible for the inclusion of patients. When a patient is 
included a unique RNH number is attributed to the patient. The GP records patient 
characteristics, i.e. birthdates, sex, educational level, insurance, type of household, 
marital status, place of residence, date of entry, last update and end of registration. 
The GP records all relevant health problems, only permanent, chronic and recurrent 
(>3 recurrences within a period of 6 months) are recorded, or when they had lasting 
consequences for the functional status or prognosis of the patient. Medication 
prescriptions (coded according to the Anatomical Therapeutic Chemical Index 2012 
by the WHO Collaborating Centre for Drug Statistics Methodology) are included in 
the RNH database Registration. This includes type of medication, start and end date, 
and dose. Diagnoses are coded in a standardized fashion, according to the 
International Classification of Primary Care, using the criteria of the International 
Classification of Health in Primary Care (ICPC) and the current guidelines of the 
Dutch College of GPs [15]. Monitoring by the RNH registry ends at migration or 
death. All practices use MicroHIS (Torex-Hiscom), a commercially developed 
general practice health information software program containing a basic module, a 
medical module and a pharmacy module, which enable the GP to keep up an 
automated registration of his patients. Quarterly the RNH data collection module 
enables the GP to exchange all registered data to the central database. The RNH 
assistant checks the data and the RNH test module provides the distribution of the 
practice population, e.g. tables with the age distribution and the twenty most 
registered ICPC codes. The RNH exports the database in an SPSS data format.  
A number of instruments are available in order to improve the quality and 
to reduce the inter-doctor variation: all GPs participating in the RNH are instructed 
and trained, RNH help program exists with all guidelines and criteria described, 
regional consensus group meeting take place at least 4 times a year to discuss their 
registration difficulties, special software for data control in the health information 
system used by the GP and, special software for data control in the central database, 
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several quality control experiments have been performed to gain insight into the 
quality of the database and several measures of agreement were done [14, 16]. 
 
Data analysis 
Chronic diseases are selected from the classification from chronic diseases 
of Knottnerus [17]. We have included all chronic diseases, only congenital diseases 
have been excluded. Using ATC code J01 for all antibacterial medication for 
systemic use, further discrimination is made for antibiotic classes used in general 
practice, i.e. tetracycline (ATC J01A), penicillins (ATC J01C), sulphonamides and 
trimetroprim (ATC J01E), macrolides (ATC J01F), fluoroquinolones (ATC J01MA) 
and nitrofuran derivates (ATC J01XE). Antifungals (J02) and anti-tuberculosis drug 
(J03) excluded All other medication present at the moment when antibiotics have 
been prescribed are considered co-medication. Co-medication is registered in the 
following groups of medication: drugs for peptic ulcer and gastro-esophageal reflux 
(ATC A02B), antithrombotic agents (ATC B01A), cardiovascular medication (ATC 
C), corticosteroids for systemic use (ATC H02), anti-inflammatory and anti-
rheumatic products, non-steroids anti-inflammatory drugs (ATC M01A), other 
analgesics and antipyretics (ATC N02B), anxiolytics (ATC N05B), hypnotics and 
sedatives (ATC N05C), antidepressants (ATC N06A), and antihistamines for 
systemic use (ATC R06). Since 1996 the RNH is recording all ADEs as ICPC code 
A85. All kinds of ADEs could be recorded at the discretion of the attending GP. 
ADEs are considered associated with antibiotic prescription if occurring within four 
weeks after start of antibiotics. The ADEs are self-reported by patients and were 
recorded as an ADE at the discretion of the attending GP.  
 
Statistical analysis and ethics 
Unit of analyses are patient years, where a patient contributed one patient-
year when he or she had attended a GP in that calendar year. Outcome measures 
included in the analyses are: antibiotic prescriptions (yes/no in a year), the number 
of antibiotic prescriptions (cumulated within a patient over a year) and ADEs 
(yes/no in a year). For antibiotic prescriptions, a multivariate model was build 
including age, time, gender, education level and rural versus and urban general 
practice, and chronic disease. In analyses with ADE as outcome restricted the study 
population to patient-years with antibiotic prescription and the multivariate model 
included age, time, gender, education level and rural versus and urban general 
practice, chronic disease and co-medication. The variables on age and time were 
presented, as these were our main focus, while controlling for the other variables. 
Interaction terms between age and time were explored. Statistical analysis is done 
with SPSS 16.0. A p-value <0.05 is considered statistically significant. 
All patients included in the RNH database have been informed about the 
potential anonymous use of their health information. If a patient does not agree, the 
inclusion of this patient in the RNH database is stopped. All data in this study were 
analyzed anonymously, only medications and clinical data were used. The Medical 
Ethics Committee of the Maastricht University Medical Center approved this study 
(METC 12-4-053).  
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Results 
 
A total of 658,940 patient years were analyzed from 2000-2009: 43% 
(n=280,417) of the patients years were aged between 18-44 years, 36% (n=237,524) 
between 45-64 years, 16% (n=108,131) between 65-79 years and 5% (n=32,868) 
≥80 years. Forty eight percent (n=318,621) of the patient years were comprised by 
male and 52% (n=340,319) were comprised by female, see Table 1 for population 
characteristics of the RNH.  Sociodemographical characteristics of samples in other 
studies, which made use of the RNH database, have shown to be comparable to the 
Dutch population [16]. The elderly (>65 years) are slightly overrepresented in the 
RNH, 22% compared to 14% in the Dutch population in 2007. Hence, we do 
consider our results to be accurate and representative for the Dutch population, with 
a high internal and external generalizability. 
In total 11.5% (n=75,796) of the patient years at least one antibiotic per 
year was prescribed. Antibiotics were more often prescribed in elderly patients 
(P<0.001), as shown  in Figure 1. The association with higher age was present in all 
years studied. Prescription rates of all antibiotics increased in all age-categories over 
time (all P<0.001). Although an increase was observed in all age categories, the 
increase was strongest in patients >80 years (interaction between age and time: 
P<0.001).  This increase is seen for all antibiotic classes, with the exception of the 
macrolides (Figure 2). The number of antibiotic prescriptions per patient per year 
increased with age (P<0.001): two or more antibiotic courses were prescribed for 
18% (n=1,571) of the patients years in 18-44 years, 19% (n=5,042) in 45-64 years, 
23% (n=3,581) in 65-79 years and 29% (n=1571) in ≥80 years. The number of 
prescriptions independently increased with age and independently increased over 
time (P<0.001).  
 
Table 1. Population characteristics of the RNH in patient years. 
 Antibiotic prescription Total 
No Yes 
Age categories    
● 18-44 yr 252,120 (43%) 28,297 (37%) 280,417 (43%) 
● 45-64 yr 210,943 (36%) 26,581 (35%) 237,524 (36%) 
● 65-79 yr 92,691 (16%) 15,440 (20%) 108,131 (16%) 
● >80 yr 27,390 (5%) 5,478 (7%) 32,868 (5%) 
Gender    
● Male 289,966 (50%) 28,655 (38%) 318,621 (48%) 
● Female 293,178 (50%) 47,141 (62%) 340,319 (52%) 
Education    
● Secondary school or lower secondary 
vocational education 
188,361 (32%) 30,161 (40%) 218,522 (33%) 
● Senior secondary vocational education 81,523 (14%) 11,905 (16%) 93,428 (14%) 
● Higher education and University 26,248 (5%) 3,352 (4%) 29,600 (5%) 
● Unknown 287,012 (49%) 30,378 (40%) 317,390 (48%) 
Chronic disease    
● No 369,062 (63%) 39,161 (52%) 408,233 (62%) 
● Yes 214,082 (37%) 36,635 (48%) 250,717 (38%) 
General Practice    
● Rural 386,365 (66%) 45,900 (61%) 432,265 (66%) 
● Urban 196,779 (34%) 29,896 (39%) 226,675 (34%) 
Total 583,144 (85%) 75,796 (15%) 658,940 (100%) 
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Figure 1. Percentage of patients years with at least one antibiotic prescription that year in different age 
categories during 2000-2009 (P<0.001).  
 
 
ADEs, underlying diseases and co-medication 
Of all patients who received an antibiotic prescription, the minority (2%; 
n=1,526/75,796) reported an ADE in the four weeks time window. In a random 
sample of 4 week periods from the same patients, compared to any 4 week period, 
excluding antibiotic prescriptions during this period, rates found were 0.06% 
(n=425/658,346) without antibiotics. No time trend in ADE reporting was observed. 
ADEs were not reported more frequently in the later years (2008/2009) compared to 
the earlier years (2000/2001). ADEs increased per age category per calendar year  
from 1.8% in 18-44 years, 1.9% in 45-64 years and 2.3% in 65-79 years to 2.8% in 
≥80 years. However, co-medication also increased per age category from 23% 
(n=6,529) in 18-44 years, 49% (n=13,078) in 45-64 years and 70% (n=10,978) in 
65-79 years to 78% (n=4,275) in ≥80 years. As expected, underlying chronic 
diseases increased by age. Of all patient years analyzed 18% (n=50,924) were 
diagnosed with at least one chronic disease, 40% (n=94,376) in the 45-64, 72% 
(n=77,530) in 65-79 and 85% (n=27,887) in >80 years age category. In the 
univariate analysis older age, having one or more chronic disease and co-medication 
were associated with occurrence of ADE. In the multivariate analysis use of co-
medication remained associated with ADE (P<0.001) (Figure 3), while age and 
chronic disease were not.  
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Figure 2. Percentage of patients with at least one antibiotic prescription that year for different classes of 
antibiotic prescriptions in different age categories during 2000-2009 (P<0.001).  
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Figure 3. Percentage of adverse drug events with number of co-medication per age category during 2000-
2009. 
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Discussion 
 
This large primary cohort shows that the rate of antibiotic prescribing for 
patients who made a visit to the GP has increased in Dutch general practice from 
2000 to 2009 in all adult age categories. We have observed the highest increase in 
the rate of antibiotic prescriptions in elderly patients; from 9% of patients receiving 
at least one antibiotic in 2000 to 22% in 2009. Additionally, elderly patients more 
often receive two or more antibiotic prescriptions per patient than younger patients. 
We have shown increasing trends for all antibiotic subgroups. This is particularly 
striking for the fluoroquinolones, as these are not indicated as first choice in any 
Dutch general practice guideline. In the United States nonapproved fluoroquinolone 
prescribing has already been described in 2005 [18]. Only the macrolides have 
shown a stable prescription pattern over time and across groups. Elderly patients 
have more ADEs associated with antibiotics. Co-medication has been identified as 
the only independent determinant for ADEs. Age was not an independent variable in 
the multivariate analysis.  
Our finding that the antibiotic prescription is increasing since 2005 in the 
Netherlands is comparable with the increase in Europe as shown in the European 
Surveillance of Antimicrobial Consumption data [19]. Although, the prescription 
rate in the Netherlands is increasing, it is still low compared to other European 
countries [19]. The Dutch guidelines for GPs of common infections have not been 
changed significantly during these ten-years. However, the increase of the number of 
fluoroquinolone prescriptions suggests that guidelines are not always followed. The 
increase in antibiotic prescriptions might be explained by an increased consultation 
frequency for acute infections, such as RTIs and UTIs. Although, the consultation 
frequency historically has tended to decrease over the years [20], it was recently 
shown that consultation rates for lower RTIs are increasing in the Netherlands while 
RTI related consultations are stable in the UK [21]. In this study however, we did 
not have access to the ICPC coding for acute conditions such as acute respiratory 
tract infections. 
To our knowledge only three previous studies, one in England/Wales, one 
in New Zealand and one in Italy, have shown higher antibiotic consumption in 
elderly patients (>75 years) [2, 3]. We showed that elderly patients consistently have 
high antibiotic prescription rates compared to the younger patients and there is an 
increasing trend over time as well in these elderly patients. 
The highest risk group to develop ADEs is aged over 80 years with multiple 
co-morbidity and co-medication [22, 23]. Inappropriate prescriptions are a leading 
cause for the development of ADEs [24, 25]. Although, the observed rate of ADEs 
in our study is lower than the 5-35% found in other studies [26-28]. Our study is in 
line with studies that show that co-medication and the number of co-medication is an 
independent association with ADEs due to antibiotic use [23, 29]. To prevent ADEs 
in elderly patients due to antibiotic use, the necessity of antibiotic treatment needs to 
be carefully determined, especially when co-medication is used. Minimizing 
unnecessary antibiotic treatment by even a small percentage could significantly 
reduce immediate and direct risks of ADE in individual patients [30]. 
The main strengths of this study are the long study period and the large 
representative study group. Since 1996 this RNH database is keeping records of all 
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medications (including antibiotics) via a computerized medical registration program. 
Data accuracy can be guaranteed as data extraction takes place from electronic 
medical records of practices and regular training of the GPs and quality controls of 
the data take place [14, 16]. All patients with multiple antibiotic prescriptions per 
year have been included only once per year. Therefore, this study group is not biased 
by a few fragile elderly patients with multiple antibiotic prescriptions.  
However, this study has several limitations. Firstly, antibiotic prescriptions 
could not be given in daily defined dosages (DDDs) like some international data [31, 
32], limiting comparability with other studies. Secondly, we have no diagnostic 
information on acute infections. Thirdly, ADEs were self-reported by the patients, 
most probably underestimating the incidence of ADE associated with antibiotics.  
Based on our findings, future strategies to decrease the antibiotic 
consumption and antibiotic resistance in the Netherlands should be addressed to all 
adult age categories. The elderly could be a specific target group and more in-depth 
study into the reasons for increasing antibiotic prescribing is necessary.  
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Abstract 
 
Introduction. Ciprofloxacin is a broad-spectrum antimicrobial drug for which 
therapeutic drug monitoring (TDM) has been suggested. A simple and rapid method 
to determine ciprofloxacin concentrations in serum is described.  
Methods. The method has been validated for linearity, precision, accuracy and 
stability, following the guidelines for industry bioanalytical method validation 
recommended by the Food and Drug Administration (FDA). Serum samples were 
precipitated with acetonitril. An RP-HPLC method with fluorescence detection was 
used (excitation and emission wave lengths for ciprofloxacin were 278 and 440 nm, 
respectively). The calibration range was 0.5 to 10.0 mg/L. Three quality controls 
(0.8, 4 and 8 mg/L) were tested.  
Results. The intra- and inter-assay variability was within 7.5%. The lower limit of 
quantification (LLOQ) was determined at 0.2 mg/L. The freeze-and-thaw, the short-
term, long-term, the stock solution and post-preparation stability were all determined 
and adequate. The extraction recovery was 82%, 87% and 88% at respectively 0.8, 4 
and 8 mg/L.   
Conclusion. This simple and fast method is suitable for TDM and pharmacokinetic 
studies. 
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Introduction 
 
The quinolone ciprofloxacin is a broad-spectrum antimicrobial drug, with 
bactericidal activity against both Gram-positive and Gram-negative bacteria. 
Individual therapeutic drug monitoring (TDM) is widely accepted for gentamicin 
and vancomycin. Although it has been suggested that TDM would also be useful for 
other antibiotics such as ciprofloxacin [1-5], this is not standard of care in the 
majority of hospitals.  
A large number of high performance liquid chromatography (HPLC) 
methods have been described to determine ciprofloxacin concentrations in biological 
fluids, mainly in plasma and serum. The most commonly used technique is HPLC 
with ultra violet (UV) or fluorescence detection, extensively reviewed by Carlucci 
[6]. In this review [6] and in studies after 1998 [7, 8] complex methods for sample 
preparation with one or more than one extraction step have been used to determine 
ciprofloxacin blood levels. In general sample preparation methods based on 
extraction are slow and time consuming compared to protein precipitation. 
Moreover, an internal standard is not included in most of the studies in this review 
[6], although inclusion of an internal standard in samples extraction methods 
increases the quality of ciprofloxacin determination [7, 8]. On the other hand simple 
sample preparation methods have not always been validated as extensively as 
recommended by the Food and Drug Administration (FDA) of the USA [9]. The aim 
of this study is to develop and to validate a simple and reliable method for the 
quantification of ciprofloxacin levels in human serum. Such a method would be very 
valuable for studies evaluating TDM of ciprofloxacin in an era of increasing 
ciprofloxacin resistance.   
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Material and methods 
 
Chemicals  
Ciprofloxacin hydrochloride (pure Ph Eur) was used as analytical standard 
(AppliChem, Darmstadt, Germany). Methanol (Lichrosolv
®
 grade), acetonitrile 
(Lichrosolv
®
 grade), phosphoric acid (Pro-analysi grade) and ethanol (Emsure
TM
 
grade) were purchased from Merck (Darmstadt, Germany). 
 
Chromatography 
The RP-HPLC system consisted of an automatic sampler injector (model 
717, Waters USA), a pump (model 1050, Hewlett Packard, New York), a Waters 
Atlantis T3 column (4.6x150mm;5µm) and an fluorescence detector (JASCO FP-
920). The mobile phase consisted of a phosphor buffer (pH 3.0) and acetonitrile 
(85:15), degassed with helium. Ciprofloxacin levels were determined with a flow 
rate of 2.0 mL/min, at an excitation wavelength 278 nm and emission wavelength 
440 nm. 
 
Preparation of calibration standards and quality controls 
Two independent stock solutions of ciprofloxacin (400 mg/L) were 
prepared. Ciprofloxacin samples for calibration curves were made by dissolving 
8.88 mg of ciprofloxacin hydrochloride in 10 mL of ethanol and 10 mL in H2O 
(factor weight 387.84). For complete dissolution the mixture was placed for 5 
minutes in an ultrasonic bath. This ciprofloxacin stock was used for the preparation 
of the calibration standards. Five calibration standards were prepared by adding the 
required amount of ciprofloxacin in blank human plasma to obtain concentrations of 
0.5, 1, 2, 5 and 10 mg/L of ciprofloxacin. Another batch of ciprofloxacin stock 
solution was used to prepare 3 different concentrations of quality control samples 
(0.8, 4 and 8 mg/L). The required amount of ciprofloxacin was added to blank 
human plasma to obtain concentrations of 0.8, 4 and 8 mg/L. The quality controls 
were stored in separate containers at -20º C.  
 
Sample preparation 
Plasma samples (250 µL) for the calibration and the quality controls (QCs) 
were transferred into Eppendorf tubes and mixed with acetonitrile (250 μL) for 
protein precipation. After 15 minutes centrifugation at 10.800 rpm the clear 
supernatant was injected (10 µL). 
 
Validation 
Validation followed the Guidance for industry bioanalytical method 
validation recommended by the Food  and Drug Administration (FDA) of the USA 
[9]. The RP-HPLC method was validated for linearity, precision, accuracy and 
stability. Six calibration curves were constructed independently on six different 
days. The calibration curves (1/x) were considered linear when correlation 
coefficient (r
2
) was higher than 0.99. Three QCs (0.8, 4 and 8 mg/L) were prepared 
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and analyzed on six times on one day and one time on six different days to 
determine intra- and interday precision and accuracy of the RP-HPLC assay. The 
precision coefficient of variation should not exceed 15% of the actual value except 
for the lower limit of quantification (LLOQ), where it should not exceed 20%. 
Freeze and thaw stability was determined after 3 cycles. Short term temperature 
stability at room temperature was investigated by analyzing 3 QCs after 4-24 hours. 
Long-term stability of ciprofloxacin at -20
◦
 C was determined by analyzing 3 QCs 
after 1 month and 7 months. Stock solution stability was evaluated at room 
temperature for 6 hours. Post preparative stability was determined for 12 hours. 
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Results 
 
Calibration curve and standard curve 
The preparation time was simple in a short time; one precipitation step with 
acetonitril and one 15 minutes centrifugation step. After the sample preparation the 
chromatographic analysis with 9 minutes run time was performed. The retention 
time of ciprofloxacin was 7.6 minutes (Figure 1). The calibration curves were linear, 
the correlation coefficients of the calibration curves were all higher than 0.99 
(r
2
=0.9983, n=6). An example of a calibration curve is shown in Figure 1. The 
Lower Limit of Quantification (LLOQ) was 0.2 mg/L (precision 5.1%; accuracy -
11%; n=5).  
 
 
 
Figure 1. Chromatogram of ciprofloxacin 1 mg/L in blank human plasma.  
 
 
Accuracy, precision and recovery 
The intra-assay precision and accuracy were within 7.5% (Table 1). The 
inter-assay precision and accuracy were within 15% (Table 1). The extraction 
recovery (in duplo) was 81.6%, 86.9% and 88.0% for respectively 0.8, 4 and 8 
mg/L. The quadratic relationship between the measured serum concentration and the 
standard deviation (SD) is presented in Figure 2. The error pattern of the assay can 
be described by the following polynomial equation: SD = 0.001 + 0.048C + 0.002C
2
 
(r
2
 = 1.000). This polynomial equation can be used to calculate the SD 
corresponding with each plasma concentration (C). 
 
 
 
 
 
 
RP-HPLC method to determine ciprofloxacin levels 
 
49 
 
 
Table 1.  Intra- and interassay precision and accuracy of ciprofloxacin RP-HPLC assay 
CV: coefficient of variation; SD: standard deviation 
 
 
 
Figure 2. Error pattern of the ciprofloxacin RP-HPLC assay (n=6). 
 
 
Stability 
Freeze and thaw stability of ciprofloxacin was better than 97% after 3 
cycles for all three concentrations. The short term room temperature stability (in 
duplo) after 4 hours was 98% for 0.8 mg/L, 94% for 4 mg/L and 95% for 8 mg/L. 
This was 91% for 0.8 mg/L, 92% for 4 mg/L and 90% for 8 mg/L after 24 hours. 
The long term stability (in duplo) at -20
◦
 C of 0.8 mg was 103%, 4 mg was 97% and 
8 mg was 100% after 7 months. Stock solution stability at room temperature after 6 
hours was 100%. Stock solution stability at refrigeration (6-8 °C) was 103% after 3 
weeks. The post-preparative stability (in duplo) in the auto sampler after 12 hours 
was 96% for 0.8 mg/L, 96% for 4 mg/L and 97% mg/L for 8 mg/L. 
 Intra-assay (n=6) Inter-assay (n=6) 
True 
conc. 
(mg/L) 
Mean 
(mg/L) 
SD 
(mg/L) 
Precisi
on CV 
(%) 
Accu-
racy (%) 
Mean 
(mg/L) 
SD 
(mg/L) 
Precisi
on CV 
(%) 
Accu-
racy 
(%) 
0.8 mg/L 0.71 0.050 7.09 -11.25 0.78 0.04 5.20 -2.13 
4 mg/L 3.96 0.164 4.15 -1.08 4.04 0.22 5.50 0.95 
8 mg/L 7.71  0.305 3.90 -3.96 7.92 0.42 5.33 -1.01 
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Discussion 
 
A simple RP-HPLC method with fluorescence detection for the 
measurement of ciprofloxacin has been developed and validated in our laboratory. 
Our RP-HPLC method is acute and precise with only one protein precipitation step 
and without an internal standard. An internal standard is very important in extraction 
methods. In extraction methods the internal standard has to be very similar to the 
material that has to be extracted. In protein precipitation this is not necessary; an in 
internal standard is mainly useful for injection fluctuations. Nowadays the injection 
fluctuations are very low in automatic injection sampler machines. Our method is 
simpler and faster compared to similar methods [10-12]. All these studies are more 
time consuming; Imre et al. [10] has a complicated mobile phase with a gradient 
profile, Wu et al. and Maya et al. [11, 12] have used an UV detector with an internal 
standard. Furthermore in all these studies [10-12] the chromatographic analysis time 
is longer, respectively 12 minutes, 12 minutes and 14 minutes. Our chromatographic 
analysis time is 9 minutes per sample.  
Our method has been extensively validated, as recommended by the FDA 
[9]. All aspects of accuracy, precision, recovery, calibration curves and stability are 
satisfactory; therefore this simple and fast method is reliable. Serum samples can be 
stored without loss of ciprofloxacin concentration for at least 7 months in -20º C. 
Also the post-preparative stability was satisfactory during at least 12 hours. 
Therefore 80 samples can be measured within each run (9 minutes per sample). This 
fast method is suitable in TDM and/or for other studies requiring ciprofloxacin 
concentrations. 
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Abstract 
 
Introduction. The aim of this study was to determine the ciprofloxacin serum 
concentrations in hospitalised patients and to determine which percentage reached 
the efficacy target of AUC24/MIC>125. Additionally, the influence of demographic 
anthropomorphic and clinical parameters on the pharmacokinetics and 
pharmacodynamics of ciprofloxacin were investigated. 
Methods. In serum of 80 hospitalised patients ciprofloxacin concentrations were 
measured with reverse phase high performance liquid chromatography with 
fluorescence detection. The ciprofloxacin dose was 400-1200 mg/day iv in two or 
three doses depending on renal function and causative bacteria. Pharmacokinetic 
parameters were calculated with maximum a posteriori Bayesian estimation 
(MW\PHARM 3.60). A two-compartment open model was used. 
Results. Mean (+sd) age was 66 (+17) years, the mean clearance corrected for 
bodyweight was 0.24 L/h/kg and the mean AUC24 was 49 mg×h/L. Ciprofloxacin 
clearance and thus AUC24 were associated with both age and serum creatinine. Of 
all patients, 21% and 75% of the patients, did not reach the proposed ciprofloxacin 
AUC24/MIC>125 target with MICs of 0.25 and 0.5 mg/L, respectively. A computer 
simulated increase in the daily dose from 800 mg to 1200 mg, decreased these 
percentages to 1% and 37%, respectively. 
Conclusion. A substantial proportion of the hospitalised patients did not reach the 
target ciprofloxacin AUC24/MIC and are suboptimal dosed with recommended 
doses. Taken into account the increasing resistance for ciprofloxacin worldwide, a 
ciprofloxacin dose of 1200 mg iv daily in patients with a normal renal function is 
necessary to reach the targeted AUC24/MIC>125. 
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Introduction 
 
Ciprofloxacin, a broad-spectrum antimicrobial drug, has been extensively 
used in inpatient and outpatient settings. The probability of cure of an infection has 
been shown to be dependent on the 24 hours area under the curve (AUC24) of 
ciprofloxacin and the minimal inhibitory concentration (MIC) for specific bacteria 
[1-5]. The quotient AUC24/MIC needed for a high probability of cure varies in 
different studies. AUC24/MIC>125 was found to be predictive of microbiological 
and clinical cure in patients with serious Gram-negative infections and in Intensive 
Care Unit (ICU) patients [3, 5]; microbiological cure was reached in 86% above and 
in 26% below this breakpoint and clinical cure in 82% above and in 42% below this 
breakpoint [5]. Using a clinical outcome-based Monte Carlo simulation, it was 
shown that in patients with Enterobacteriaceae bacteraemia an AUC24/MIC>250 was 
associated with cure rates of 91% in patients with values above and of 29% below 
this breakpoint [4]. Moreover in nosocomial pneumonia dose alterations based on 
plasma drug concentration and bacterial MIC value improved the probability of 
good clinical outcome and pathogen eradication [6]. 
In the nineties, it was shown that 80% of treatment failures during 
ciprofloxacin treatment were due to drug resistance [7]. The MIC predicted clinical 
response, especially in patients with infections caused by organisms for which the 
MICs were at the marginal points of susceptibility. Development of resistance to 
ciprofloxacin was largely confined to marginally susceptible organisms such as 
Staphylococcus aureus, Streptococcus pneumoniae and Pseudomonas aeruginosa. 
Recently Enterobacteriaceae were added to this marginally susceptible group based 
on a Monte Carlo simulation [4]. Both MIC and resistance for ciprofloxacin are 
steadily increasing. In the Netherlands ciprofloxacin resistance increased from 1 to 
15% in Escherichia coli and from 1 to 13% in Klebsiella pneumoniae from 2001 
untill 2009, and in susceptible bacteria MICs increased [8, 9]. In Greece 
ciprofloxacin resistance for E. coli increased from 9% in 2001 to 23% in 2009 and 
ciprofloxacin resistance for K. pneumoniae increased from 54% to 66 % from 2005 
to 2009% [10]. 
With increasing MICs, the targeted AUC24/MIC>125 may be less often 
reached, resulting in increasing ciprofloxacin resistance and higher clinical failure 
rates. Indeed, Perreiter et al. calculated with a population model from the literature 
that 66% reached the minimum AUC24/MIC target of >100 [11], Neef et al. found in 
2002 from an in vitro model that 1200 mg was the optimal dose to be given if the 
MIC was 0.25 mg/L [12] and recent studies on critically ill patients on ICUs have 
shown that the AUC24/MIC target of >125 is reached in only 31-84% of the patients 
[1, 3]. In these studies AUC24 of ciprofloxacin was usually low, respectively 42 ± 36 
[1] and 57 ± 33.5 mg×h/L [3].  In a recent study in 25 critically ill patients with 
chronic obstructive pulmonary disease low AUC24 values and high variability of 
kinetic parameters were found with ciprofloxacin 1200 mg [13]. However, 
ciprofloxacin is also widely used in patients admitted to the general hospital wards 
and only sparse data regarding ciprofloxacin AUC24/MIC are available in this 
particular population. Therefore, we have measured ciprofloxacin blood levels in 
patients admitted to such wards that were given ciprofloxacin intravenously (iv) and 
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evaluated the AUC24/MIC ratio. Additionally, the influence of demographic 
anthropomorphic and clinical parameters on the pharmacokinetics and 
pharmacodynamics of ciprofloxacin were investigated. 
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Methods 
 
Study design  
Patients above 18 years of age with iv ciprofloxacin treatment hospitalised 
at the Maastricht University Medical Centre (MUMC), a 715 bed university 
hospital, admitted to general wards were included from April 2009 until April 2010. 
Ciprofloxacin blood levels were measured in samples drawn for routine assays. 
Patients with minimal two blood levels available were included. Ciprofloxacin Kabi 
(Fresenius Kabi, Bad Homburg, Germany) was started at the discretion of the 
attending physician, usually when an infection was suspected or cultured pathogens 
proved susceptible to ciprofloxacin. Ciprofloxacin was dosed from 400 to 1200 
mg/day in two or three doses; the standard dose was 800 mg/day, 400 mg/day was 
prescribed when the creatinine clearance was less than 30 ml/min and 1200 mg/day 
was prescribed for patients with a P. aeruginosa infection and normal renal function. 
A solution for infusion of 2 mg/ml (400mg/200ml and 200mg/100ml) was used. The 
400mg/200ml infusion was run in 60 minutes and the 200mg/100ml was run in 30 
minutes. Demographic and clinical data, i.e. age, gender, weight, co-medication, 
ciprofloxacin dose, times of ciprofloxacin doses and blood collections, serum 
creatinine, admission days, C-reactive protein (CRP) and culture results were 
retrieved from the electronic patient file (iSoft, the Netherlands). Creatinine 
clearance was calculated with the Modification of Diet in Renal Disease formula 
(MDRD). Cultures were performed and ciprofloxacin MICs were determined as 
standard clinical care with the Becton Dickinson Phoenix
TM
 Automated 
Microbiology System (Franklin Lakes, New Jersey, USA) using the ID/AST Combo 
panels UNMIC/ID53 and NMIC/ID75 for Gram negative bacteria and the AST 
panel PMIC-58 for Gram positive bacteria. Clinical outcome was defined by CRP 
decrease, number of admission days and clinical cure (defeveresence, 
microbiological cure and discharge from the hospital). 
This study was registered at the Dutch Trial Register (NTR 1725) and was 
approved by the Medical Ethical Committee of the MUMC (MEC 08-4-063). 
 
HPLC analysis 
A simple, fast and specific method for measuring ciprofloxacin serum 
levels has been validated for linearity, precision, accuracy and stability, following 
the guidelines for industry bioanalytical method validation recommended by the 
Food and Drug Administration (FDA) [14]. In short, serum samples were 
precipitated with acetonitrile. A reverse phase high pressure liquid chromatography 
method with fluorescence detection was used (excitation and emission wave lengths 
for ciprofloxacin were 278 and 440 nm, respectively). The calibration range was 0.5 
to 10.0 mg/L. Three quality controls (0.8, 4 and 8 mg/L) were tested. The intra- and 
inter-assay variability was within 7.5%. The lower limit of quantification was 0.2 
mg/L. The freeze-and-thaw, the short-term, long-term, the stock solution and post-
preparation stability were all determined and adequate. The extraction recovery was 
82%, 87% and 88% at respectively 0.8, 4 and 8 mg/L [15].  
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Pharmacokinetic analysis 
Pharmacokinetic parameters of ciprofloxacin in individual patients were 
calculated with maximum a posteriori Bayesian estimation program (MW/PHARM 
3.60, Mediware, the Netherlands). We used a two-compartment open 
pharmacokinetic model based on a previous clinical study [5]. The AUC24 was 
calculated from 48 to 72 hours after start of therapy, assuming a steady state is 
reached.  
 
Statistical analysis 
Metric variables are tested for normality of distribution by the Shapiro-
Wilk test. If normally distributed, means and standard deviations are used to 
characterize the univariate distributions, if not; score ranges are also given. 
Categorical variables are presented as frequencies and percentages. Scores for main 
outcome parameter (CL/W of ciprofloxacin) turned out to be non-normally 
distributed and had to be 
10
log-transformed to validly perform parametric tests. 
Univariate analysis on 
10
log-CL/W with categorical variables is either done by 
Student t-test or by one-way ANOVA (using the Bonferroni correction for 
polychotomous categories). Pearson correlation coefficients (r) for this outcome 
with the dichotomous predictor (gender) and metric variables are also presented. All 
data analysis is done with SPSS-pc version 16.0. A P-value of <0.05 is considered to 
be statistically significant.  
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Results 
 
Study group 
A total of 80 patients with a median of 4 (range: 2 to 7) blood samples were 
included. The average age was 66 years and 60% were male (Table 1). One third 
was diagnosed as having pneumonia and 10% had sepsis (Table 1). Patients were 
admitted throughout all wards of the hospital. Co-medication did not interfere with 
pharmacokinetic parameters of ciprofloxacin (data not shown). 
At least one culture was taken from all patients; 21 urine cultures, 20 blood 
cultures, 15 sputum cultures, 15 wound cultures and 9 cultures of drains and/or 
abdominal fluid. Forty five of the 80 patients (58%) had a positive culture. Of the 
positive cultures 35 (78%) were Gram-negative bacteria; E. coli (n=12), Klebsiella 
spp. (n=10), Enterobacteriaceae (n=6), Proteus spp. (n=4) and P. aeruginosa (n=3). 
In urine cultures MICs were not determined lower than 0.5 mg/L by the 
UNMIC/ID53 panel (standard clinical care). Therefore MIC values were available in 
27/35 (77%) in patients with a Gram negative bacterium cultured. Gram positive 
bacterium were cultured in 10/80 patients (12%); S. aureus 4/80 (5%), Enterococcus 
spp. 4/80 (5%), CNS 1/80 (1%) and S. pneumoniae 1/80 (1%). 
 
 
Table 1. Patient characteristics of 80 hospitalised patients. 
 Median (Range) 
Age (years) 68 (19-101) 
Weight (kg) 70 (32-110) 
Ciprofloxacin iv (days) 8 (2-45) 
Admission (days) 20 (5-122)   
CRP before therapy (mg/L) 203 (1-469) 
CRP after therapy (mg/L) 67 (3-405) 
Gender Frequency (Percentage) 
 Male 48 (60%) 
 Female 32 (40%) 
Infection Frequency (Percentage) 
 Pneumonia 26 (33%) 
 Wound infection 18 (23%) 
 UTI 18 (23%) 
 Sepsis 8 (10%) 
 Abdominal infection 6 (6%) 
 Other 4 (5%) 
Ciprofloxacin combination with Frequency (Percentage) 
 Monotherapy 18 (23%) 
 ß-lactam antibiotics 45 (56%) 
 Clindamycin 9 (11%) 
 Other 8 (10%) 
Comedication Frequency (Percentage) 
 None 13 (16%) 
 Cardiovascular 35 (43%) 
 Immunosupressive medication 20 (25%) 
 Diabetes mellitus 10 (13%) 
 Other 15 (19%) 
UTI, urinary tract infection. 
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Pharmacokinetic and pharmacodynamic analysis 
The average CL/W was 0.24 L/h/kg, SD: 0.13 L/h/kg (median: 0.23, range: 
0.04-0.57 L/h/kg), the average volume of distribution corrected for weight (V/W) 
was 2.5 L/kg SD: 0.9 L/kg (median: 2.5, range: 0.9-5.9), average AUC24 was 49 
mg×h/L, SD: 23 mg×h/L (median: 43, range:15-128), the average creatinine was 
148 µmol/L SD: 125 µmol/L, median: 91, range: 40-625) and 23 (29%) of the 
patients had a 400 mg dose, 1 (1%) a dose of 600 mg, 51 (64%) a 800 mg dose and 5 
(6%) 1 1200 mg dose. The interindividual variability of pharmacokinetic parameters 
is large (Table 2). Patients above 80 years had lower CL/W (P=0.001) and higher 
AUC24 compared to younger patients (P=0.04), Table 2. The ciprofloxacin efficacy 
target (AUC24/MIC>125) was reached in 100% of the patients with the current 
dosing regimens when Gram-negative bacteria have a MIC≤0.125 µg/ml, 79% of the 
patients reached this target with an MIC≤0.25 mg/L, 25% with an MIC≤0.5 mg/L 
and only 1% of the patients reached this target when the MIC≥1 mg/L (Fig. 1). In 
our study, 16/27 (59%) of all Gram-negative bacteria had a MIC≤0.125 mg/L, 3/27 
(11%) had a MIC of 0.5 mg/L and 8/27 (30%) had a MIC of 2 mg/L.   
 
 
Table 2. CLcr, CL/W, V/W and AUC24 broken down for ciprofloxacin 24-hour dose categories and age 
group.  
CLcr, creatinine clearance. 
CL/W, ciprofloxacin clearance corrected for bodyweight. 
V/W, volume of distribution corrected for bodyweight. 
AUC24, area under the curve in 24-hours. 
 
 
Analysis of influence of co-variates on pharmacokinetic and pharmacodynamic 
parameters 
To determine which covariates have an effect on pharmacokinetic and 
pharmacodynamic parameters of ciprofloxacin, a univariate analysis was done using 
a predetermined set of predictors (Table 3). In the univariate analysis CL/W was 
related to age, gender, V/W and creatinine (Table 3). No significant associations 
were found between AUC24/MIC (and AUC24) and CRP decrease or increase, 
admission days and clinical outcome (data not shown).  
24h dose 
[mg] 
N CLcr [mL/min] 
median (range) 
mean (SD) 
CL/W [L/h/kg]  
median (range) 
mean (SD) 
V/W [L/kg] 
median (range) 
mean (SD) 
AUC24 [mg×h/L] 
median (range) 
mean (SD) 
400-600  24 24 (8-184) 
39 (43) 
0.15 (0.06-0.45) 
0.17 (0.09) 
2.4 (0.9-4.4) 
2.3 (0.8) 
39 (15-78)  
41 (16) 
800  51 81 (12-162) 
81 (39) 
0.25 (0.04-0.51) 
0.26 (0.11) 
2.5 (1.2-5.9) 
2.6 (1.0) 
45 (23-128) 
52 (25) 
1200  5 131 (37-173) 
113 (52) 
0.52 (0.12-0.57) 
0.39 (0.21) 
2.7 (1.3-4.4) 
2.9 (1.2) 
44 (29-89) 
53 (27) 
Age 
group 
[years] 
N CLcr [mL/min] 
median (range) 
mean (SD) 
CL/W [L/h/kg]  
median (range) 
mean (SD) 
V/W [L/kg] 
median (range) 
mean (SD) 
AUC24 [mg×h/L] 
median (range) 
mean (SD) 
<70  41 79 (12-184) 
85 (49) 
0.27 (0.07-0.57) 
0.29 (0.13) 
2.1 (1.3-4.4) 
2.6 (0.7) 
38 (15-125) 
43 (20) 
70-80  24 55 (8-131) 
58 (40) 
0.20 (0.04-0.45) 
0.21 (0.11) 
2.4 (1.0-6.0) 
2.4 (1.2) 
47 (23-96) 
52 (22) 
>80  15 37 (12-119) 
51 (33) 
0.13 (0.06-0.37) 
0.16 (0.09) 
2.4 (0.9-5.7) 
2.3 (1.1) 
63 (24-128) 
59 (27) 
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Table 3. Univariate Pearson correlation coefficients between ciprofloxacin, 10log CL/W and predictors 
used in this study. 
 Univariate 10log CL/W 
 R P-value 
Creatinine -0.547 <0.001 
Age -0.468 <0.001 
Gender -0.165 0.072 
V/W 0.416 <0.001 
24h dose/1000 0.453 <0.001 
CL/W, ciprofloxacin clearance corrected for bodyweight. 
V/W, volume of distribution corrected for bodyweight. 
 
 
Dosing simulations 
To determine whether increasing the dose of ciprofloxacin would lead to 
sufficiently high AUC24/MIC values the AUC24 was calculated with MW/PHARM 
3.60 for all patients. When increasing the daily dose of all patients by 400 mg (i.e. 
1200 mg/24h in patients with normal renal function), 99% reached the AUC24/MIC 
target with a MIC≤0.25 mg/L and 63% reached the AUC24/MIC target with a 
MIC≤0.5 mg/L. When increasing the daily dose off all patients by 800 mg (i.e. 1600 
mg/24h in patients with normal renal function), 100% reached the AUC24/MIC target 
with a MIC≤0.25 mg/L and 91% reached the AUC24/MIC target with a MIC≤0.5 
mg/L (Figure 1). 
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Figure 1. Calculated percentage of patients with an adequate AUC24/MIC ratio>125 at MIC 0.125, 0.25, 
0.5, 1.0 and 2.0 mg/L for increasing ciprofloxacin dosages based on the pharmacokinetics obtained at 
current dosage regimens.     
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Discussion 
 
This study shows that the majority of hospitalised patients using 
ciprofloxacin have low AUC24 with current iv dose regimens. A substantial part (21-
75%) of hospitalised patients on general wards did not reach the target AUC24/MIC 
ratio when the MIC is between 0.25-0.5 mg/L. A ciprofloxacin daily dose of 1200 
mg may be more effective, but fear for adverse drug events (ADEs) might hamper 
the use of this dosage. In general ciprofloxacin is considered safe and is well 
tolerated [16-18], even in higher doses [5, 19]. Most common ADEs are mild; 
gastrointestinal reactions (nausea and diarrhoea), but CNS toxicity (anxiety, 
restlessness and seizures) occurs, as do skin reactions and hepatotoxicity [16-18, 
20]. However, even at high dose seizures are rarely reported [18]. The 
pharmacodynamic better dose of 1600 mg/day cannot yet be recommended, 
although to our knowledge no increase in frequency or severity of ADE has been 
described. The variability in pharmacokinetic parameters is high, therefore dosing 
should be optimised individually. The ciprofloxacin dose is adjusted to the 
individual renal clearance
 
to prevent high ciprofloxacin levels. However, other 
covariates, such as age also influence the ciprofloxacin clearance independently. 
Adjusting for all co-variates might not be feasible and therapeutic drug monitoring 
(TDM) could further prevent high and low ciprofloxacin blood levels and could be 
useful in reaching the target AUC24/MIC ratio. Although TDM for ciprofloxacin has 
been advocated [1, 3-6], it is not standard of care in most hospitals. Taken together, 
with increasing MICs of Gram-negative bacteria, higher daily doses of ciprofloxacin 
seem necessary and feasible with regard to ADEs and TDM may be the appropriate 
tool to decrease development of ciprofloxacin resistance.  
A limitation of this study is that no effect of low AUC24/MIC ratio on 
clinical outcome could be demonstrated. Although cultures were taken in all 
patients, in only 44% Gram negative bacteria could be cultured. Furthermore, the 
group that used ciprofloxacin monotherapy was small. A different study and much 
larger numbers of patients are needed for this endpoint. On the other hand, low 
AUC24 were shown in our study and low AUC24/MIC ratio’s and worse clinical 
outcome has been shown in several studies [4-6].  
 
Conclusion 
The majority of hospitalised patients did not reach the target AUC24/MIC 
ratio with the current iv doses. Taken into account the increasing resistance for 
ciprofloxacin worldwide, TDM and subsequent dose adjustment may decrease 
development of ciprofloxacin resistance. A large randomized clinical trial of 
ciprofloxacin treatment is needed to confirm the AUC24/MIC>125 or higher 
AUC24/MIC ratios (>250) are needed for good clinical and microbiological outcome. 
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Abstract 
 
Introduction. The pharmacodynamic (PD) efficacy target of amoxicillin is 40% 
time above the minimal inhibition concentration (40%T>MIC). Recent studies of 
other antibiotics have shown that PD-efficacy targets are not always reached. The 
aim of this study was to evaluate the percentage of hospitalised patients, using 
amoxicillin/clavulanic acid intravenously (iv), that reach the pharmacodynamic 
efficacy target 40%T>MIC. Additionally, the association of demographic 
anthropomorphic and clinical parameters with the pharmacokinetics and 
pharmacodynamics of amoxicillin were determined.  
Methods. In serum of 57 hospitalised patients amoxicillin concentrations were 
measured using high performance liquid chromatography. Patients were older than 
18 years and most patients had an abdominal infection. The standard 
amoxicillin/clavulanic acid dose was 4 times a day 1000/200 mg iv. 
Pharmacokinetic parameters were calculated with maximum a posteriori Bayesian 
estimation (MW\Pharm 3.60). A one-compartment open model was used. Individual 
dosing simulations were performed with MW\Pharm. 
Results. In our study population, the mean (±SD) age was 67 (±16) years and the 
mean clearance corrected for bodyweight was 0.17 (±0.07) L/h/kg. Only, 65% of the 
patients reached the proposed amoxicillin 40%T>MIC with amoxicillin/clavulanic 
acid for bacterial MICs of 8 mg/L. A computer simulated increase of the standard 
dose to 6 times daily, increased this percentage to 95%. In this small study group 
40%T>MIC was not associated with clinical or microbiological cure.  
Conclusion. A substantial proportion of the hospitalised patients did not reach the 
40%T>MIC with the standard dose amoxicillin/clavulanic acid for a bacterial MIC 
of 8 mg/L. Therefore, we suggest increasing the standard dose of 
amoxicillin/clavulanic acid to 6 times a day in patients with severe 
Enterobacteriaceae infections. 
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Introduction 
 
In vitro and animal studies have shown that β-lactam antibiotics for Gram-
positive bacteria and Gram-negative bacteria are effective when the percentage time 
above the minimal inhibition concentration (%T>MIC) of the unbound serum 
concentration is more than 35-40%. Maximal effects are reached with %T>MIC 
above 60-70% [1-3]. Only sparse pharmacokinetic/pharmacodynamic (PK/PD) data 
are estimated in human clinical studies. Pharmacokinetic analysis of 
amoxicillin/clavulanic acid has mostly been done in healthy individuals [4, 5]. In 
human clinical studies amoxicillin/clavulanic acid has been found to cure 
Streptococcus pneumoniae and Haemophilus influenza infections clinically and 
microbiologically when %T>MIC was ≥40% [1]. To our knowledge, there are no 
human pharmacodynamic efficacy studies for Enterobacteriaceae.  
 Amoxicillin/clavulanic acid is a commonly used broad spectrum antibiotic. 
Clavulanic acid extends the spectrum of amoxicillin to β-lactamase producing 
strains, such as E. coli, K. pneumoniae, H. influenzae and S. aureus. Clavulanic acid 
has very little intrinsic antibacterial  effect. Clavulanic acid irreversibly inhibits β-
lactamase, protecting amoxicillin [6]. Therefore, amoxicillin is measured for 
determining the PD-efficacy target. Susceptibility patterns of Enterobacteriaceae 
have changed over time, and recent studies have shown that efficacy targets of other 
antibiotics, such as ciprofloxacin [7, 8], ceftazidim [9] and gentamicin [10] are not 
reached in a significant percentage of patients. In the EUCAST rationale document 
the target attainment rates for different doses of amoxicillin for different MICs based 
on Monte Carlo simulations are reported [11]. Amoxicillin blood levels have not 
been measured in these simulations. The aim of this study was to measure the 
amoxicillin serum concentrations in hospitalised patients using amoxicillin-
clavulanic acid intravenously (iv) and to determine if the efficacy target of 
40%T>MIC was reached. Additionally, we have investigated the association of 
demographic anthropomorphic and clinical parameters with pharmacokinetics and 
pharmacodynamics of amoxicillin. 
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Methods 
 
Study design  
Patients above 18 years of age treated with amoxicillin/clavulanic acid iv 
and hospitalised at the Maastricht University Medical Centre (MUMC), a 715 bed 
university hospital, were included from January 2010 until October 2010. 
Amoxicillin blood levels were measured in residual samples drawn for routine 
assays. Patients with at least two blood samples available were included and blood 
samples taken during or within 0.5 hours after infusion were excluded. 
Amoxicillin/clavulanic acid (Sandoz, Holzkirchen, Germany) was started at the 
discretion of the attending physician, either empirically or as therapy for bacteria 
susceptible to amoxicillin/clavulanic acid. The standard dose of 
amoxicillin/clavulanic acid was 1000/200 mg 4 times a day and 1000/200 mg 2 
times a day was prescribed when the creatinine clearance (CLcr) was 10-50 mL/min. 
Amoxicillin/clavulanic acid 1000/200 mg/100 mL infusion was infused in 30 
minutes. Demographic and clinical data, such as age, gender, weight, temperature, 
co-medication, length of hospital stay, time of administration of 
amoxicillin/clavulanic acid and laboratory parameters, such as, serum creatinine, C-
reactive protein (CRP) were retrieved from the electronic patient file (iSoft, the 
Netherlands). Clinical outcome was defined by CRP normalisation, number of 
admission days, and discharge from the hospital, time to defeveresence and 
microbiological cure. CLcr was calculated with the Cockroft-Gault formula using 
the lean body mass.  
This study was registered at the Dutch Trial Register (NTR 1725) [12] 
and was approved by the Medical Ethical Committee of the Maastricht University 
Medical Centre (MEC 08-4-063).  All data in this study were analysed anonymously 
and amoxicillin blood levels were measured in residual samples drawn for routine 
assays. Therefore, no consent was required from the patient. This is in agreement 
with the Medical Research Involving Human Subjects Act, the code for proper use 
of human tissue as formulated by the Dutch Federation of Medical Scientific 
Societies and the policy of the Medical Ethics Committee of the Maastricht 
University Medical Centre.  
 
HPLC analysis 
A simple, fast and specific method for measuring amoxicillin serum levels 
has been validated for linearity, precision, accuracy and stability, following the 
guidelines for industry bioanalytical method validation recommended by the Food 
and Drug Administration (FDA) [13]. In short, serum samples were precipitated 
with perchloric acid 3%. A reverse phase high pressure liquid chromatography (RP-
HPLC) method was used. The calibration range was 10 to 200 mg/L. Six quality 
controls (8, 20, 40, 60, 80 and 160 mg/L) were tested. The intra- and inter-assay 
variability was within 7.5%. The relationship between plasma concentration and sd 
was fitted with a polynomial of second order [14]. With this polynomial the lower 
limit of quantification with a precision of 20%  has been calculated and was 0.8 
mg/L [15]. All our measured concentrations were above 0.8 mg/L. 
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Pharmacokinetic analysis 
Pharmacokinetic parameters of amoxicillin in individual patients were 
calculated with maximum a posteriori (MAP) Bayesian estimation program 
(computer program MW/Pharm 3.60, Mediware, the Netherlands). A one-
compartment open pharmacokinetic model was used. With MAP Bayesian 
estimation [16, 17] all patient characteristics and measured amoxicillin 
concentrations are fitted on an existing population model [4, 5]. With two 
concentrations per patient individual pharmacokinetic parameters can be adequately 
calculated with MAP Bayesian estimation [17]. With these individual fitted 
pharmacokinetic parameters, dosing simulations were made to adjust the dose 
individually; this MAP Bayesian estimation is standard procedure in laboratories 
which provide therapeutic drug monitoring service. A population kinetic model from 
our population was not made. The free fraction of amoxicillin was fixed at 80%. The 
%T>MIC was determined with the formula of Turnidge; %T>MIC= 
ln(Dose/VdxMIC) × T½/ln(2) x 100/dosing interval [18]. Individual dosing 
simulations were performed with MW-Pharm (3 times 1000-2000 mg, 4 times 2000 
mg, 5 times 1000-2000 mg, 6 times 1000-2000 mg). 
 
Microbiological analysis 
Identification of the causative bacterium (ID) and antibiotic susceptibility 
testing (AST) were performed with the Becton Dickinson Phoenix
TM
 Automated 
Microbiology System (Franklin Lakes, New Jersey, USA) using the ID/AST Combo 
panels UNMIC/ID53 and NMIC/ID75 for Gram negative bacteria and the AST 
panel PMIC-58 for Gram positive bacteria. In urine cultures the lowest MIC 
detectable was 0.5 mg/L by the UNMIC/ID53 panel (standard clinical care). MIC 
values were not determined by the Becton Dickinson Phoenix
TM
 for Streptococcal 
spp. and Anaerobes. Susceptibility testing for Streptococcal spp. and Anaerobes was 
done with the disc diffusion method.  
 
Statistical analysis 
Metric variables were tested for normality of distribution by the Shapiro-
Wilk test and presented as mean (±SD). If not, median and ranges were also given. 
Categorical variables are presented as frequencies and percentages. Univariate 
analysis on the amoxicillin clearance corrected for bodyweight (CLam/W) with 
categorical variables was either done by Student t-test or by one-way ANOVA. Data 
analysis was done with SPSS-pc version 16.0. A P-value of <0.05 is considered to 
be statistically significant.  
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Results 
 
Study group 
A total of 57 patients with a mean (±SD) of 3 (±0.9) blood samples 
(median: 2, range 2-5 blood samples) were included. The mean age was 67 (±16) 
years (median: 69, range 23-93 years) and 70% were male (Table 1). About half of 
the patients had an abdominal infection, 18% a wound infection and 10% a 
pneumonia (Table 1).  
 
Table 1. Characteristics of 57 hospitalised patients. 
 Mean (±SD)  Median (range) 
Age in years 67 (±16) 69 (23-93) 
Weight in kg 78 (±20) 75 (43-153) 
Number of blood levels 3 (±0.9)  2 (2-5) 
Amoxicillin iv days 13 (±9) 10 (3-57) 
Admission days 27 (±34) 19 (4-188) 
Gender Number (percentage) 
 Male 40 (70%) 
 Female 17 (30%) 
Infection Number (percentage) 
 Abdominal infection 28 (49%) 
 Wound infection 10 (17.5%) 
 Pneumonia 6 (11%) 
 Urinary Tract Infection 3 (5%) 
 Other 10 (17.5%) 
Amoxicillin combination  Number (percentage) 
 Monotherapy 44 (78%) 
 Ciprofloxacin 4 (7%) 
 Erythromycin 3 (5%) 
 Gentamicin 3 (5%) 
 Othera 3 (5%) 
Co-medication Number (percentage) 
 None 16 (28%) 
 Cardiovascular 27 (47%) 
 Diabetic mellitus 15 (26%) 
 Immunosuppressive 3 (5%) 
 Otherb 8 (14%) 
aOther: rifampicin, cefuroxim and metronidazol  
bOther: haloperidol, levothyroxine, painkillers, anticoagulant  
 
Pharmacokinetic and pharmacodynamic analysis 
The mean CLam/W was 0.17 (±0.07) L/h/kg (median: 0.16, range: 0.05-
0.37 L/h/kg) and the mean volume of distribution corrected for bodyweight (V/W) 
was 0.31 (±0.07) L/kg (median: 0.30, range: 0.19-0.50 L/kg). The mean volume of 
distribution (V) was 24 (±5.6) L (median: 24, range: 14-36 L) and the mean 
elimination half-life (t½) was 1.5 (±0.6)  h (median: 1.3, range: 0.6-3.29 h) which is 
in the same range as described in the EUCAST rationale document [11]. The mean 
serum creatinine was 90 (±36) µmol/L (median: 90, range: 49-210 µmol/L). Fifty-
five (96%) patients received the standard dose of amoxicillin/clavulanic acid 4 times 
a day 1000/200 mg iv, 1 patient 3 times 1000/200 mg iv and 1 patient 2 times a day 
1000/200 mg iv, both because of renal insufficiency. Patients above 70 years had  
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lower CLam/W (P=0.02), Table 2. A significant correlation was found between 
CLam/W and age (P<0.001).   
The measured concentrations of amoxicillin were plotted against the 
sampling times in Figure 1. There was a good linear correlation (R
2
=0.96) between 
the amoxicillin actual measured concentration and estimated concentration with 
MAP Bayesian fitting (MW/Pharm 3.60, Mediware, the Netherlands), Figure 2. The 
amoxicillin efficacy target the (40%T>MIC) was reached in 100% of patients with a 
bacterial MIC≤2 mg/L of Gram negative bacteria, in 93% of patients with a MIC=4 
mg/L and in 65% of patients with a MIC=8 mg/L (Figure 3). When divided in age 
categories, arbitrarily set at 70 years; all patients older than 70 years reached the 
40%T>MIC with a MIC of 4 mg/L and 87% of the patients younger than 70 years. 
For a MIC of 8 mg/L, the 40%T>MIC was reached in 81% of the patients older than 
70 years and in 52% of the patients younger than 70 years (Figure 3).  
 
Table 2. Mean (±SD) CLam/Wa, CLcrb, V/Wc and T½d for amoxicillin in patients using 
amoxicillin/clavulanic acid broken down per age group. 
Age 
group in 
years   
N CLam/W in  
L/h/kg  
CLcr in 
 mL/min 
 
V/W in 
 L/kg 
T½  
in h 
 
<70 31 0.19 (±0.08) 82 (±25) 0.30 (±0.06) 1.26 (±0.44) 
>70 26 0.14 (±0.06) 55 (±19) 0.32 (±0.08) 1.83 (±0.71) 
P-value  0.02  <0.01 0.82 <0.01 
aCLam/W: amoxicillin clearance corrected for bodyweight 
bCLcr: creatinine clearance 
cV/W: volume of distribution corrected for bodyweight 
dT½: amoxicillin half life  
 
 
Figure 1. The measured concentrations of amoxicillin plotted against the time after amoxicillin 
administration. 
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Figure 2. Correlation between amoxicillin actual measured concentration and estimated with maximum a 
posteriori Bayesian fitting (MW/Pharm 3.60, Mediware, the Netherlands). 
 
 
 
Figure 3. The percentage of patients that reach the 40%T>MIC for different age categories at different 
MICs. 
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Analysis of influence of co-variates on pharmacokinetic and pharmacodynamic 
parameters 
To determine which co-variates have an effect on the pharmacokinetic 
parameters of amoxicillin, a univariate analysis was done using a predetermined set 
of predictors (Table 3). In the univariate analysis CLam/W was related to age, 
creatinine, CLcr, V/W and 40%T>MIC. Linear correlations were found between 
CLam/W, creatinine and age (R
2 
0.327), Vd (R
2
 0.370) and age (R
2 
0.227). In the 
univariate analysis age was not correlated to creatinine (R 0.10, P=0.467) and no 
linear correlation (R
2 
0.01) was found.  
 
Table 3. Univariate Pearson correlation coefficients between amoxicillin/clavulanic acid,  
CLam/W and predictors used in this study. 
 Univariate CLam/W 
 R P-value 
Creatinine -0.584 <0.001 
Age -0.476 <0.001 
Gender -0.034 0.812 
V/W -0.608 <0.001 
40%T>MIC -0.424 0.025 
CLam/W, amoxicillin/clavulanic acid clearance corrected for bodyweight 
V/W, amoxicillin/clavulanic acid volume of distribution corrected for bodyweight 
 
Dosing simulations 
To determine whether increasing the dose of amoxicillin/clavulanic acid 
would lead to sufficiently high %T>MIC, the %T>MIC was calculated for all 
patients with increasing doses with the Turnidge formula [18]. When increasing the 
dosage frequency from 4 times to 6 times a day all patients with bacterial MIC≤4 
reach the efficacy target and 95% (54/57) of the patients with bacterial MIC≤8 
(Figure 4). 
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Figure 4. Calculated percentage of patients with 40%T>MIC at different MICs for increasing amoxicillin 
dosages. 
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Microbiological analysis 
Sixteen out of twenty one abdominal fluid cultures became positive, 8/10 
wound cultures, 7/16 blood cultures, 4/5 urine cultures and  1/2 sputum cultures 
became positive. Of three patients no cultures were taken. In total thirty-six of the 57 
patients (63%) had a positive culture. Of the positive cultures, 30 (83%) were 
Enterobacteriaceae; E. coli (n=21), Klebsiella spp. (n=6), Enterobacter spp. (n=2) 
and Proteus spp. (n=1). In three patients two bacteria were isolated. Of the Gram 
positive cultures, 6 were Enterococcus spp, 3 Staphylococcus aureus and 1 
coagulase negative staphylococcus.  Forty MIC values were available in 36 patients. 
Of the isolated Enterobactericeae 17/30 (57%) of had a MIC≤4 mg/L, 4/30 (13%) 
had a MIC=8 mg/L and 9/30 (30%) had a MIC≥16 mg/L. Of the isolated Gram 
positive bacteria 8/10 (80%) of had a MIC≤1 mg/L and 2/10 (20%) had a MIC≥4 
mg/L. Clinical cure was reached in 46 patients, 8 patients switched antibiotic 
therapy and in 3 patients cure was not reached (of which two died). No significant 
associations were found between 40%T>MIC and defeverescence, CRP decrease or 
increase, admission days and clinical outcome (data not shown). 
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Discussion 
 
In this study, we demonstrate that the efficacy target of 40%T>MIC for 
amoxicillin/clavulanic acid was reached in 93% of the patients tested when the MIC 
was 4 mg/L and only in 65% of the patients tested when the MIC was 8 mg/L. In the 
EUCAST and CLSI criteria Enterobacteriaceae are considered to be susceptible for 
amoxicillin/clavulanic acid with bacterial MIC≤8 mg/L [11]. High bacterial MICs 
for amoxicillin/clavulanic acid are an increasing problem in the Netherlands and in 
Europe [19, 20]. To prevent treatment failure for individual patients and to prevent 
development of antibiotic resistance on population level, increasing the standard 
dose of amoxicillin/clavulanic acid seems warranted. Dosing simulation showed that 
increasing the standard dose of amoxicillin/clavulanic acid to 6 times a day 
1000/200 mg increased the number of patients reaching 40%T>MIC to 100% for 
bacterial MIC≤4 and to 95% with bacterial MIC≤8. Continuous iv dosing is an 
alternative for frequent dosing of time dependent β-lactam antibiotics. 
Unfortunately, amoxicillin is not very suitable for continuous iv dosing, because of 
the instability of amoxicillin at room temperature. Therefore, we suggest increasing 
the dose of amoxicillin/clavulanic acid to 6 times a day in patients with severe 
Enterobacteriaceae sepsis or intra-abdominal infection.  
In general amoxicillin/clavulanic acid is well tolerated. The most frequent 
adverse drug events are diarrhoea, nausea and vomiting. However, 
amoxicillin/clavulanic acid is also associated with liver injury, which is estimated to 
occur from 1 to 1.7 per 10.000 users [21, 22]. Clavulanic acid seems to be 
responsible for the adverse drug reaction, since amoxicillin alone is rarely associated 
with liver injury and causes less gastrointestinal problems than the combination 
preparation [23-25]. In vitro pharmacodynamic studies demonstrate that low dose of 
clavulanic acid suffice and the β-lactamase inhibition of clavulanic acid lasts for 8-
12 hours [26, 27]. Therefore, increasing the standard dose of amoxicillin/clavulanic 
acid of 4 times a day 1000/200mg iv with amoxicillin twice daily 1000 mg iv may 
be a safe and effective alternative.  
CLam/W is correlated with CLcr and the amoxicillin dose is adjusted with 
to the CLcr. However, other covariates also influence the CLam/W. CLam/W was 
significantly correlated with age. However, age and creatinine were not correlated to 
each other, meaning that elderly patients can have both a normal creatinine and a 
decreased CLam/W. Therefore, the correlation of age with CLam/W seems 
independent of the creatinine.  Furthermore, the 4 patients that did not reach the 
efficacy target with bacterial MIC=4 were all young patients with excellent 
clearance. Our measured attainment results are lower than those calculated 
attainment results in the EUCAST rationale document, in which Monte Carlo 
simulations were used to calculate  the target attainment rates (40%T>MIC) of 
different dosing regimens (from 500 mg 3 times a day to 2 g 4 times a day) for 
different bacterial MICs (0.5-32 mg/L) [11]. The target attainment in the EUCAST 
rationale document for the standard dose (1000/200 mg 4 times a day) is 100% at 
bacterial MIC≤4 and 75% with bacterial MIC≤8 mg/L [11]. In our real life blood 
level determination study, these percentages were 93% and 65%, respectively. This 
difference may be explained by the larger interindividual variability of our 
population and in particular by a group of younger patients with normal renal 
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clearance (CLcr>60 mL/min). Remarkably, in the EUCAST rationale document, the 
interindividual variation is extremely small; t½ is 1.1 (±0.1) h, versus t½ is 1.5 
(±0.6) h in our study. The higher t½ in our study may be due to the high mean age of 
our population.  
No significant associations have been found between the target 40%T>MIC 
and clinical outcome. As expected, our study population was too small and too 
heterogeneous. A large number of patients are needed to draw conclusions for this 
endpoint. Moreover, in an in vitro study, ceftazidim has been shown to be 
maximally effective when 40%T>MIC was reached for concentrations four times 
the MIC or higher [28]. In our study, the target of  40%T>4×MIC was only reached 
in 100% for low MICs (≤1 mg/L), but never for bacterial MICs of 4 and 8 mg/L. 
Our study was not designed to isolate a large number of bacterial MICs and 
therefore only a limited number of clinical bacterial MICs were available in our 
study. Taken together a large clinical PK/PD study of amoxicillin/clavulanic acid is 
needed with microbiological and clinical cure endpoints to establish the association 
between clinical endpoints and the efficacy target 40%T>MIC.  
 
Conclusions 
The current standard dose of amoxicillin/clavulanic acid 4 times a day 
1000/200 mg iv is too low to reach the 40%T>MIC for bacterial MIC of 8 mg/L in a 
high percentage of patients. To prevent treatment failure for individual patients and 
to prevent development of antibiotic resistance on population level, we suggest 
increasing the standard dose of amoxicillin/clavulanic acid to 6 times a day in 
patients with an Enterobacteriaceae sepsis or intra-abdominal infection.  
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Abstract 
 
Introduction. To compare vancomycin pharmacokinetic parameters in patients with 
and without neutropenia. 
Methods. Patients ≥18 years admitted on general wards were included. Routinely 
vancomycin trough and peak plasma concentrations were measured with a 
fluorescence polarization immunoassay. Pharmacokinetic parameters of individual 
patients were determined with maximum a posterior Bayesian estimation (MW 
Pharm 3.60). Neutropenia was defined as neutrophils <0.5109cells/L.  
Results. A total of 171 patients were included. Patients with neutropenia (n=56) had 
higher clearance of vancomycin (CLva), 67 (±26) mL/min, compared to patients 
without neutropenia (n=115), CLva 50 (±22) mL/min (P<0.001). No significant 
difference was found in serum creatinine and vancomycin volume of distribution. 
Neutropenia was positively associated with CLva, independently of relevant co-
variables (B: 12.122, 95%CI: 1.095 to 23.149, P=0.031). On average patients with 
neutropenia needed 33% higher doses of vancomycin to attain adequate exposure, 
i.e. AUC24400 mgh/L. Furthermore, 15 initially neutropenic patients in our study 
group received vancomycin for a second administration period. Ten patients 
received the second administration period during another neutropenic period and 5 
patients during a non-neutropenic phase. All 5 patients with vancomycin during both 
neutropenic and non-neutropenic phase had higher CLva (91 (±26) mL/min) during 
the neutropenic period and lower CLva (45 (±10) mL/min) during the non-
neutropenic phase (P=0.009). 
Conclusion. This study shows that most patients with neutropenia have augmented 
CLva. In a small group of patients that received vancomycin during two episodes, 
the augmented CLva seems to be reversible in the non-neutropenic period. Our data 
indicate that it is important to increase the daily dose with one third in patients with 
neutropenia (from 15 mg/kg twice daily to 13 mg/kg three times daily). Frequent 
performance of therapeutic drug monitoring in patients with neutropenia may 
prevent both therapy failure due to low AUCs and overcomes toxicity due to high 
vancomycin trough concentrations during recovery from neutropenia.  
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Introduction 
 
Mortality from infections after cytostatic conditioning regimens in 
hematologic neutropenic patients requiring hematopoietic cell transplantation is high 
[1]. Bacterial infections are common during neutropenic phases and antibiotics, such 
as vancomycin, are often required [2]. In a recent surveillance study, Gram positive 
organisms are the most common cause of bacteremia in hematology patients, i.e. 
coagulase negative staphylococci (36%), followed by, Streptococci (11%), S. aureus 
(8%) and Enterococci (4%) [3].  Antibiotics should be started within 1 hour in 
patients with severe sepsis. However, adequate dosing of vancomycin can be 
difficult. Augmented clearance has been increasingly described in critically ill 
patients at the Intensive Care Unit (ICU) [4-6]. Changes in volume of distribution 
(Vd), changes in renal function and severe hypoalbuminemia are often present, 
influencing vancomycin plasma concentrations. Augmented clearance of 
vancomycin leads to lower vancomycin plasma concentrations, decreased 24-hour 
area under the curve (AUC24) and leads to diminished clinical outcome [6]. 
Augmented clearance of vancomycin in patients with hematological malignancies 
has been reported, but the augmented clearance was not associated with population 
specific covariables [7]. In another study low teicoplanin trough concentrations in 
neutropenic patients were reported, suggesting augmented clearance of teicoplanin 
in neutropenic patients [8]. In addition, elevated clearance of piperacillin and 
ceftazidime has also been noticed in patients with febrile neutropenia [9, 10]. The 
mechanism of augmented clearance of antibiotics is not completely understood and 
is poorly investigated in patients with hematologic malignancies or in patients with 
neutropenia. The aim of this study is to compare vancomycin pharmacokinetic 
parameters in patients with and without neutropenia at non-ICUs in a University 
Hospital.  
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Methods 
 
Study group 
In this observational study patients were prospectively followed. Patients 
older than 18 years treated with vancomycin intravenously (iv) and hospitalized at 
the Maastricht University Medical Centre (MUMC), a 715 bed university hospital, 
were included from May 2011 until July 2013. Patients were excluded when 
admitted at the ICU or when insufficient data was collected. Vancomycin was 
started at the discretion of the attending physician, either empirically or as therapy 
for bacteria susceptible to vancomycin. Dose individualization was applied since an 
initial loading dose of 15 mg/kg was followed by dose adjustment based on 
therapeutic drug monitoring (TDM) and renal function. Demographic and clinical 
data, such as age, gender, weight, temperature, co-medication, length of hospital 
stay, time of administration of vancomycin and laboratory parameters, such as, 
serum creatinine (Jaffé method), and leucocytes were retrieved from the electronic 
patient file (SAP®, the Netherlands). Neutropenia was defined as <0.5109 cells/L. 
Creatinine clearance (CLcr) was calculated with the Cockcroft and Gault formula 
[(140 - age in years)  weight in kg] / [serum creatinine in µmol  factor] using 
total bodyweight [11]. 
 
Ethics statement 
This study was conducted according to the principles expressed in the 
Declaration of Helsinki. This study was registered at the Dutch Trial Register (NTR 
1725). The Medical Ethical Committee of the Maastricht University Medical Centre 
(MEC 08-4-063) approved this study and waived the necessity to obtain informed 
consent from participants because of the observational design. Electronic health 
records were anonymized prior to use. 
 
Measurement of vancomycin 
Vancomycin plasma concentrations were measured as standard clinical care 
with a fluorescence polarization immune assay using of Cobas Integra 800 system 
(Roche Diagnostics®). The calibration curve ranged from 2.0 to 80 mg/L. The 
accuracy and coefficients of variation (CV) of the controls (6.9, 17.7 and 31.0 mg/L) 
were within 90%-110% and <3.3%, respectively. Patients with at least two plasma 
samples available, drawn in such a manner to ensure calculations of vancomycin 
clearance (CLva) were included. Blood samples were collected at least one hour 
after the end of infusion and trough levels were obtained just before the next dose.  
 
PK-analysis 
Pharmacokinetic parameters (CLva, Vd) of vancomycin in individual 
patients were calculated with maximum a posterior (MAP) Bayesian estimation 
computer program (MW/Pharm 3.60, Mediware, the Netherlands). Bayesian priors 
from a two compartment open pharmacokinetic model based on previous studies, 
were applied: V1 0.21 ± 0.04 L/kg, kelm 0.0143 ± 0.0029 h
-1
, kelr = kslope  CLcr 
(mL/min), 0.00327 ± 0.00109 h
-1
/mL/min, k12 1.12 ± 0.28 h
-1
, and k21 0.48 ± 0.12 h
-1
 
[12, 13], where V1 is volume of distribution central compartment (L/kg); kelm, 
metabolic elimination rate constant (h
-1
);  kslope, renal elimination rate constant (h
-
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1
/mL/min); kelr, renal elimination rate constant (h
-1
);  k12 (h
-1
), rate constant from the 
1
st
 to the 2
nd
 compartment; and k21(h
-1
) , vice versa. The elimination rate constant kel 
= kelm + kelr = kelm + (kslope  CLcr) [14]. With MAP Bayesian estimation all patient 
characteristics and measured vancomycin concentrations are fitted on an existing 
population model. With at least two concentrations per patient individual 
pharmacokinetic parameters can be adequately derived with MAP Bayesian 
estimation [15, 16]. With these individual pharmacokinetic parameters, dosing 
simulations were made to adjust the dose individually; this MAP Bayesian 
estimation is a standard procedure in institutes which provide TDM service. 
The AUC24 in steady-state was calculated with the formula:  24-hour 
dose/CLva.  
 
Analysis of patients with and without neutropenia 
Pharmacokinetic, clinical and demographic parameters were compared in 
patients with and without neutropenia in all patients and in patients with 
hematological malignancies. Furthermore, pharmacokinetic parameters of two 
vancomycin administration periods within the same patients were compared. Both 
patients with two vancomycin administrations during two different neutropenia 
periods and patients with two vancomycin administrations during one neutropenia 
period and one period without neutropenia were compared.  
 
Statistical analysis 
Normal distribution was evaluated for metric variables  by means of the 
Shapiro-Wilk test and presented as mean (±SD). If not, median and ranges were 
given. Categorical variables are presented as frequencies and percentages. Metric 
and categorical variables were evaluated between patients with and without 
neutropenia using the Student t-test or non-parametric test (Kruskal Wallis), 
respectively. 
First, the influence of co-variables on CLva was determined in univariable 
(Pearson) analysis. Subsequently, only the significant co-variables in the univariable 
analyses were included in the multivariable analysis, after checking the assumptions. 
The Enter method was used in the multivariable linear regression. CLcr is estimated 
with the C&G formula which includes serum creatinine, age, weight and gender 
[11]. To avoid multicollinearity, serum creatinine, age, weight and gender were left 
out of the multivariable model. Data analysis was done with IBM SPSS-pc version 
20.0. A p-value of <0.05 was considered to be statistically significant. 
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Results 
 
Study group 
The mean age was 59 (±14) years and 61% were male. Patients were 
admitted on different general wards; hematology ward (40%, 68/171), surgery ward 
(19%, 32/171), internal ward (11%, 19/171), neurosurgery ward (11%, 18/171), 
orthopedic ward (10%, 17/171), cardiac (9%, 15/171) and eye ward (1%, 2/171). 
The majority of patients had sepsis (46%, 79/171), implant infection (16%, 27/171) 
or abdominal infection (15%, 25/171). A total of 171 patients with a mean (±SD) of 
6 (±3) vancomycin plasma concentrations were included.  
 
Pharmacokinetics analysis 
The mean dose (±SD) of vancomycin per 24 hours was 1683 (±759) mg, 
with a mean Vd of 58 (±30) L and AUC24 of 502 (±97) mgh/L. The mean (±SD) 
trough concentration in steady state (SS) was 13 (±4) mg/L, CmeanSS was 21 (±4) 
mg/L, peak concentration in SS was 49 (±14) mg/L, CLva was 56 (±25) mL/min and 
serum creatinine was 89 (±68) µmol/L.  
 
Analysis of patients with and without neutropenia 
Sixty eight patients had a hematological malignancy and 56 patients were 
neutropenic, Figure 1. Neutropenic patients (n=56) had higher CLva, 67 (±26) 
mL/min, compared to non-neutropenic patients (n=115), CLva 50 (±22) mL/min 
(P<0.001). No significant difference in serum creatinine and Vd was found, Table 1 
and Figure 1. Forty eight percent (27/56) of the neutropenic patients had CLva>70 
mL/min, compared to 21% (24/115) without neutropenia. Of the 68 patients with a 
hematological malignancy, 55 patients were neutropenic and 13 were not 
neutropenic. Within the hematologic malignancy patients, neutropenic patients had 
higher CLva, than non-neutropenic patients, Table 1 and Figure 2. Physicians used 
TDM and adjusted vancomycin dosing as shown by the mean dose of vancomycin in 
patients with neutropenia of 2017 (±720) mg compared to 1521 (±727) mg in 
patients without neutropenia, P<0.001. On average, among patients with neutropenia 
the daily vancomycin dose was 33% (500 mg/day) higher to achieve the same 
AUC24 (Table 1). Patients with sepsis (n=79) had higher CLva and were younger 
than patients without sepsis (n=92). Vd and CLcr were not different, Table 2. 
Neutropenic patients with sepsis (n=47) seemed to have slightly higher CLva of 69 
(±27) mL/min than neutropenic patients without sepsis (n=9) CLva 60 (±22) 
mL/min, P=0.269. Both neutropenic patients with sepsis and without sepsis had 
higher CLva than non-neutropenic patients. 
Of the 171 patients, 15 neutropenic patients received a second period of 
vancomycin, of which 5 patients received vancomycin during both an neutropenic 
and non neutropenic period. Ten patients received two vancomycin episodes during 
neutropenic periods. However, 3 patients developed kidney failure and were taken 
out. Leaving 7 patients with two vancomycin periods during neutropenia, Figure 1. 
Therefore, the data of 7 patients with two neutropenic periods and 5 patients with 
both a neutropenic and non-neutropenic period could be compared. The median 
(range) of time between the two vancomycin administrations was 30 (20-108) days 
for these 7 patients and 21 (14-136) days for the 5 patients with both a neutropenic  
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Figure 1. Flow of the 171 included patients with regard to hematology, neutropenia and two vancomycin 
administration periods.  
 
 
Table 1. Mean (±SD) for Age, CLcr, CLva, Vd, Dose 24 h and AUC24 of patients with and without 
neutropenia in all patients (A) and in patients with haematological malignancy (B) 
A] All patients (n=171) 
Neutro- 
penia    
N Age 
year 
CLcr  
mL/min  
CLva 
mL/min 
Creatinine 
µmol/L 
Vd 
L 
Dose 24h 
mg 
AUC24  
mg×h/L  
No  11
5 
61(±14) 107 (±78) 50(±22) 95(±67) 56(±29) 1521(±727) 499(±102) 
Yes  56 55(±13) 113 (±57) 67(±26) 80(±31) 62(±32) 2017(±719) 507(±87) 
P  0.01 0.142 <0.001 0.873 0.304 <0.001 0.259 
B] Patients with haematological malignancy (n=68) 
Neutro- 
penia    
N Age 
Year 
CLcr  
mL/min  
CLva 
mL/min 
Creatinine 
µmol/L 
Vd 
L 
Dose 24h 
mg 
AUC24  
mg×h/L  
No 13 57(±11) 111(±58) 53(±16) 96(±59) 59(±18) 1604(±646) 502(±102) 
Yes  55 55(±14) 114(±57) 68(±26) 79(±29) 62(±32) 2040(±705) 509(±87) 
P   0.839 0.714 0.024 0.779 0.691 0.028 0.697 
CLva: vancomycin clearance 
CLcr: creatinine clearance calculated from serum creatinine with Cockcroft and Gault [11] 
Vd: volume of distribution 
AUC: 24 hour area under the curve 
 
Hematology n=68 Other n=103  
Total 171 patients 
 
neutropenia n=55 No neutropenia n=13 neutropenia 
n=1 
no neutropenia 
n=102 
15 patients with 2 periods of vancomycin 
 
5 patients with 2 periods of 
vancomycin  during neutropenic 
and non -neutropenic phase 
10 patients with 2 periods 
vancomycin during 2 
neutropenic phase 
7 patients with 2 periods 
vancomycin during 2 
neutropenic phase 
3 patients with 
kidney failure 
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Table 2. Mean (±SD) for Age, CLcr, CLva, Vd, Creatinine for patients with sepsis and without sepsis.  
 N Age  
years 
CLva  
mL/min 
Vd  
L 
CLcr  
mL/min 
Creatinine 
 µmol/L 
Sepsis  79 56 (±13) 60 (±27) 57 (±26) 108 (±56) 84 (±38) 
No sepsis 92 61 (±14) 52 (±23) 58 (±33) 110 (±83) 96 (±71) 
P  0.017 0.048 0.639 0.535 0.894 
CLva: vancomycin clearance 
CLcr: creatinine clearance calculated from serum creatinine with Cockcroft and Gault [11] 
Vd: volume of distribution 
 
 
and non neutropenic period. For the 7 patients with vancomycin administrations in 
two neutropenic periods, the CLva remained similar: 77 (±30) to 70 (±23) mL/min 
(P=0.748), as did the serum creatinine 68 (±13) to 66 (±11) µmol/L (P=0.701) and 
CLcr 120 (±41) to 117 (±35) mL/min (P=0.848). The 5 patients with vancomycin 
administrations in both a neutropenic and non-neutropenic period had a statistically 
significantly higher CLva, 91 (±26) mL/min, during the neutropenic phase compared 
to CLva, 45 (±10) mL/min during the non-neutropenic phase (P=0.009). Serum 
creatinine, 65 (±10) and 69 (±11) µmol/L (P=0.462) and CLcr, 141 (±70) and 113 
(±48) mL/min during the neutropenic and non-neutropenic periods, respectively, 
were not significantly different (P=0.402), Figure 3 and neither was the Vd was 74 
(±24) L during neutropenic and 51 (±10) L during non-neutropenic phase (P=0.175).  
 
 
C
L
v
a
 (
m
L
/m
in
)
0
20
40
60
80
100
120
140
160
C
L
v
a
 (
m
L
/m
in
)
0
20
40
60
80
100
120
140
160
all patients (n=171) patients with haematological malignancy (n=68)A B
no neutropenia            neutropenia
        n=115                           n=56
no neutropenia            neutropenia
        n=13                             n=55
P=0.024P<0.001
 
Figure 2. Boxplot for vancomycin clearance (CLva) in patients with and without neutropenia in all 
patients (A) and in patients with haematological malignancy (B). Lower and higher boundary of the 
box indicates 25th and 75th percentile, respectively, the line within the box marks the median, the whiskers 
above and below the box indicate the 90th and 10th percentiles and the open circles indicate outside the 
90th and 10th percentiles. 
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Figure 3. A. Vancomycin clearance (CLva) and B. serum creatinine of 5 patients (number 1-5) during 
both a neutropenic and a non-neutropenic phase and C. CLva and D. serum creatinine of 7 patients 
(number 1-7) during two neutropenic phases. 
 
 
CLcr, neutropenia, hematologic malignancy and sepsis were correlated with CLva in 
the univariable analysis, Table 3. In the multivariable analysis, CLva was positively 
associated with CLcr (B: 0.205, 95%CI: 0.164-0.245, P<0.001) and neutropenia (B: 
12.122, 95%CI: 1.095 to 23.149, P=0.031), Table 3. 
 
 
 
 
 
 
 
P=0.748 
P=0.701 
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Table 3. Univariable and multivariable correlation coefficients between CLva and predictors used in this 
study. 
 Univariablea Multivariableb  
 R P-value B 95% confidence  interval for B P-value 
    Lower bound Upper bound  
CLcr 0.599 <0.001 0.205 0.164 0.245 <0.001 
Neutropenia 0.322 <0.001 12.12
2 
1.095 23.149 0.031 
Hematologic 
malignancy 
0.300 <0.001 3.582 -8.404 15.569 0.556 
Sepsis 0.170 0.027 0.427 -7.236 8.090 0.913 
Vd 0.008 0.915 - - - - 
CLva: vancomycin clearance 
CLcr: creatinine clearance 
Vd: volume of distribution 
aPearson correlation was performed as the univariable analysis 
bOnly co-variates that were significantly correlated with CLva in the univariable analysis (P<0.05) were 
included in the multivariable analysis 
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Discussion 
 
Our study shows that higher doses of vancomycin are needed during 
neutropenic periods to achieve vancomycin target AUC24 and target trough 
concentrations. The augmented clearance of vancomycin in neutropenic patients 
seems reversible. Augmented clearance of vancomycin cannot be predicted with the 
estimated CLcr, as serum creatinine and estimated CLcr in our study are not 
significantly different in neutropenic and non-neutropenic patients. Moreover, the 
estimated CLcr is not reliable above 125 µmol/L and shows a poor agreement with 
measured CLcr in urine in critically ill patients displaying augmented clearance of 
creatinine [17, 18]. Our Bayesian calculated CLva is in line with the population 
estimated CLva in patients with hematological malignancies in the simulations by 
Buelga et al. [7]. However, our routine patient care observations demonstrate that 
augmented clearance is associated with neutropenia rather than hematological 
malignancy and sepsis. In the multivariable analysis neutropenia (yes/no) was 
positively associated with CLva, independently of the other co-variables. Although, 
our group of patients that received a second administration of vancomycin is small, 
the augmented clearance of vancomycin seems to be temporarily and reversible, as 
the CLva returned to normal during the non-neutropenic phase. The mechanism of 
augmented clearance is not completely clarified; most likely more than one factor is 
involved in developing augmented clearance. Young age, increased blood flow to 
the kidneys, genetic factors and other medication has been proposed to influence the 
CLva [5, 6]. Neutropenia might be added to this list. Most likely augmented 
clearance also influences other renally cleared antibiotics [9, 10]. Therefore, TDM 
of these antibiotics or/and at least one 24-hour creatinine measurement in urine to 
determine the most accurate CLcr at the ICU is recommended [5, 19, 20]. Our data 
suggest that this recommendation may be extended to neutropenic patients.  
Our study has a couple of limitations. Firstly, our study is a real-life 
observational study and we assumed the TDM protocol was strictly followed by 
clinicians, especially the timing of peak concentrations. Secondly, our group of 
patients with a second vancomycin administration was rather small to prove the 
demonstrated tendency of reversibility of elevated CLva, at the moment when 
patients are recovering from neutropenia. Further research is needed to fully 
understand the complex pharmacokinetics of vancomycin and other antibiotics in 
patients with neutropenia. A prospective study may elucidate which other factors are 
involved in augmented CLva, but such a study would need a multicentre design and 
inclusion of many patients. Until, we fully understand augmented clearance, we 
suggest to increase the initial daily dose of vancomycin with 33% (13 mg/kg three 
times daily) in patients with neutropenia and to perform TDM after the first 
vancomycin dose in patients to prevent low plasma concentrations of vancomycin 
and consequently reduced efficacy. When patients are recovering from neutropenia, 
TDM is again necessary to adjust the vancomycin dose to prevent toxicity due to 
high vancomycin exposure.  
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Abstract 
 
Background. The aim of this study is to investigate if vancomycin clearance (CLva) 
can be adequately predicted with CLva prediction methods. Additionally, other co-
variates influencing the CLva were investigated and predictivity of monitoring of 
only trough levels to 24-hour area under the curve (AUC24) was evaluated. 
Methods. Routine vancomycin plasma levels were measured with a fluorescence 
polarization immunoassay. Pharmacokinetic parameters of individual patients, i.e. 
CLva and volume of distribution, were determined with maximum a posteriori 
(MAP) Bayesian estimation. CLva was calculated with the three prediction methods, 
which are solely based on creatinine clearance (CLcr) estimated with Cockcroft and 
Gault formula, and it was compared with the calculated CLva with MAP Bayesian 
Estimation. Prediction errors were calculated. Correlations between CLva and CLcr, 
creatinine, age, weight, gender and neutropenia were made. Furthermore, 
correlations between trough levels and AUC24 were evaluated. 
Results. A total of 171 patients were included. Prediction errors and absolute 
prediction errors of the 3 methods ranged from 28-80% and 39-83%, respectively. In 
the multivariable analysis CLva was significantly associated with CLcr, creatinine, 
age, weight, gender and neutropenia. Linear correlation between AUC24 and trough 
levels was R
2
 0.38. 
Conclusions. Large prediction errors make the CLva algorithms based on estimated 
plasma CLcr unsuitable for use in patient care. Additionally, other factors, which are 
not accounted for in the current algorithms, influence the CLva individually. Due to 
low association of AUC24 and trough levels, the AUC24 cannot be predicted with 
through levels. For a reliable AUC24 guided vancomycin dosing, therapeutic drug 
monitoring is necessary.  
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Introduction 
 
Therapeutic Drug Monitoring (TDM) of vancomycin, a reserve 
glycopeptide antibiotic, in combination with maximum a posterior (MAP) Bayesian 
estimation has been routinely used in Dutch hospitals to calculate the vancomycin 
clearance (CLva) and to dose vancomycin optimally using the calculated 24 hour 
area under the curve (AUC24). TDM is needed since vancomycin is renally cleared 
and dose adjustments are necessary when kidney function is reduced to prevent 
toxicity. Furthermore, PK/PD targets (AUC24/MIC ratio) are necessary for an 
optimal antimicrobial result [1]. TDM is more labour intensive and costly, than an 
CLva prediction method based on CLcr. Therefore, an accurate prediction method 
could reduce TDM and costs. Another reason for the need of a good prediction 
model is that in some patients it may be difficult to obtain multiple plasma 
vancomycin levels. This even led to the suggestion in the Infectious Disease Society 
of America (IDSA) guidelines to monitor only trough levels of vancomycin [2].  
Several prediction methods based on the clearance of creatinine (CLcr) have been 
proposed to estimate CLva. Murphy et al. showed that seven different prediction 
methods were insufficiently reliable to replace TDM [3], but most of the tested 
prediction methods consisted of small patient groups (n=12-56). New approaches 
based on the CLcr have been proposed to predict CLva during the last years [1, 4, 5]. 
DeRyke et al. combined equations of two older studies into a new formula [6, 7].  
Pea et al. studied 70 critically ill patients retrospectively and prospectively tested his 
formula in 63 critically ill patients [4]. The key aspects of these prediction methods 
studies are summarized in Table 1. The new prediction methods were suggested to 
be more reliable than the prediction methods reviewed by Murphy et al [1, 3-5]. 
However, these new prediction methods are all based on CLcr calculated from 
serum creatinine to predict CLva. Therefore, they all depend on the method used for 
CLcr estimation from serum creatinine levels. Many different methods exist to 
estimate the CLcr, e.g. the Cockcroft-Gault (C&G) formula [8], several 
Modification of Diet in Renal Disease (MDRD) formula’s [1, 9, 10] and Chronic 
Kidney Disease Epidemiology Collaboration formula (CKD-epi) [11, 12]. It is not 
clear which of these methods should be used in the prediction methods.  
 
Table 1. Key aspects of the three vancomycin clearance prediction methods. 
 Pea et al. DeRyke et al. Moise-Broder et al. 
Patient population critically ill patients serious systemic 
infections 
S. aureus RTI 
Vancomycin dose continous infusion 30 
mg/kg 
intermittent, 15 mg/kg 
bd 
intermittent 
CLcr estimation C&G C&G C&G 
Formula: CLva=  (0.29 × CLcr) + 0.94 CLcr × 0.75 (0.79 × CLcr) + 15.4 
RTI: respiratory tract infection 
CLcr: creatinine clearance 
C&G: Cockcroft and Gault 
CLva: vancomycin clearance 
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The aim of this study is to compare the three CLva prediction methods with 
the MAP Bayesian estimated CLva. We also determined the strength of the 
association between trough levels and AUC24 in real life. Additionally, we 
investigated which method to estimate the CLcr is strongest associated with the 
CLva and which other co-variates influence the CLva. The ultimate goal is to 
determine whether TDM can be reduced with prediction methods and if dosing 
guided by trough levels only is reliable. 
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Materials and Methods 
 
Study group 
This was an observational study, which collected data from routine patient 
care. Patients older than 18 years treated with vancomycin intravenously (iv) and 
hospitalised at the Maastricht University Medical Centre (MUMC), a 715 bed 
university hospital, were included. Vancomycin was started at the discretion of the 
attending physician, either empirically or as therapy for bacteria susceptible to 
vancomycin. Dose individualization was applied since an initial loading dose of 15 
mg/kg was followed by dose adjustment based on TDM and renal function. 
Vancomycin plasma levels were measured as standard clinical care with a 
fluorescence polarization immunoassay using of Cobas Integra 800 system (Roche 
Diagnostics®). The calibration curve ranged from 2.0 to 80 mg/L. The accuracy and 
coefficients of variation (CV) of the controls (6.9, 17.7 and 31.0 mg/L) were within 
90%-110% and <3.3%, respectively. Patients with at least two plasma samples 
available, drawn in such a manner to ensure calculations of CLva, were included. 
Blood samples were collected at least one hour after the end of infusion and trough 
levels were obtained just before the next dose. Demographic and clinical data, such 
as age, gender, weight, temperature, co-medication, length of hospital stay, time of 
administration of vancomycin and laboratory parameters, such as, plasma creatinine 
(Jaffé method), and leucocytes were retrieved from the electronic patient file 
(SAP®, the Netherlands). Neutropenia was defined as <0.5109 cells/L. Patients 
were excluded when admitted at the Intensive Care Unit (ICU). This study was 
registered at the Dutch Trial Register (NTR 1725) and was approved by the Medical 
Ethical Committee of the MUMC (MEC 08-4-063). 
 
Pharmacokinetic analysis 
Pharmacokinetic parameters (CLva, volume of distribution (Vd), half-life 
(T½)) of vancomycin in individual patients were calculated with MAP Bayesian 
estimation computer program (MW/Pharm 3.60, Mediware, the Netherlands). A two 
compartment open pharmacokinetic model was used. Bayesian priors from the 
population, established and routinely used in our institute, were applied: V1 0.21 
±0.04 L/kg, kelm 0.0143 ± 0.0029 h
-1
, kslope (kelr = kslope  CLcr (mL/min)), 0.00327 
± 0.00109 h
-1
/mL/min, k12 1.12 ± 0.28 h
-1
, and k21 0.48 ± 0.12 h
-1
 [13, 14], where V1 
is volume of distribution central compartment; kelm, metabolic elimination rate 
constant; kslope, renal elimination rate constant; kelr, renal elimination rate constant; 
k12, rate constant from the 1
st
 to the 2
nd
 compartment; and k21, vice versa. With MAP 
Bayesian estimation all patient characteristics and measured vancomycin levels are 
fitted on an existing population model. With two levels per patient individual steady 
state pharmacokinetic parameters can be adequately calculated with MAP Bayesian 
estimation.[15, 16] With these individual fitted pharmacokinetic parameters, dosing 
simulations were made to adjust the dose individually; this is standard procedure in 
laboratories which provide therapeutic drug monitoring service. 
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CminSS (trough level steady state), CmeanSS and CmaxSS (peak level 
steady state) were calculated with MW/Pharm. The AUC24 in steady state (SS) was 
calculated with the formula:  24-hour dose/CLva.  
 
Comparison of CLcr estimation formulas  
CLcr was calculated with the C&G formula [(140 - age in years)  weight 
in kg] / [creatinine in µmol  factor] using total bodyweight.[8] The CLcr 
estimation formulas of Modification of Diet in Renal Disease-4 (MDRD-4)[11], 
MDRD-5 [17], MDRD-6 [10] and CKD-epi [11, 12] are described elsewhere. The 
C&G formula is based on age, weight and creatinine, the MDRD-4 is based on 
creatinine, age and sex, in the MDRD-5 formula plasma urea is added and in the 
MDRD-6 urea and albumin are added. The CKD-epi is based on plasma creatinine, 
sex, age and race [11, 12]. 
 
Performance of CLva prediction methods 
CLcr with the highest linear correlation with the CLva determined with 
TDM was used in all CLva prediction methods: i.e. Pea et al. 0.48×CLcr +15.6 [4], 
DeRyke et al. 0.75×CLcr [5] and Moise-Broder et al. 0.79×CLcr +15.4 [1]. The 
prediction bias and precision were calculated as percentage of prediction error [= 
(actual value – predicted value)/actual value × 100%] and as percentage of absolute 
prediction error [= +(actual value –  predicted value)/actual value × 100%].  
 
Dosing on trough levels 
Correlations between AUC24 and trough levels were determined. 
Attainment rates of the efficacy targets of AUC24/MIC≥400 [1], were calculated for 
measured trough levels <10, 10-15, 15-20 and >20 mg/L for simulated MIC ranges 
1-2 mg/L. 
 
Factors influencing the pharmacokinetics of vancomycin  
The influence of co-variates was determined using a predetermined set of 
predictors; correlation was calculated between CLva, CLcr, creatinine, age, weight, 
gender and neutropenia in univariable and multivariable analysis. 
 
Statistical analysis 
Metric variables were tested for normality of distribution by the Shapiro-
Wilk test and presented as mean (±SD). If not, median and ranges were given. 
Categorical variables are presented as frequencies and percentages. Univariable 
analysis on CLva with categorical and metric variables is either done by Student t-
test or by non-parametric test (Kruskal Wallis). Pearson correlation coefficients (R) 
for this outcome with the dichotomous predictor (gender) and metric variables are 
also presented. Linear correlation (R
2
) between CLcr en CLva. Bland Altmann plots 
were made for the 3 prediction methods. Pearson correlation coefficients (R) and 
linear correlation (R
2
) between trough levels and AUC24 are presented. 
The influence of co-variables on CLva was determined in univariable 
(Pearson) analysis. Subsequently, only the significant co-variables in the univariable 
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analyses were included in the multivariable analysis, after checking the assumptions. 
The Enter method was used in the multivariable linear regression. To avoid 
multicollinearity CLcr was left out of the multivariable model. Data analysis was 
done with IBM SPSS-pc version 20.0. A P-value of <0.05 was considered to be 
statistically significant. 
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Results 
 
Study group 
A total of 171 patients with a mean (±SD) of 6 (±3) vancomycin plasma 
levels were included from May 2011 until July 2013. The mean age was 59 (±14) 
years and 61% of all patients were male (Table 2). Most patients had a sepsis (46%, 
79/171), implant infection, i.e. orthopedic device, ventricular or lumbar drain and 
intravascular device (16%), abdominal infection (15%), or endocarditis (6%), Table 
2. 
 
 
Table 2. Characteristics of 171 hospitalised patients.  
 Median (range)   
Age (years) 60 (18-88)   
Weight (kg) 74 (45-149)   
Number of blood levels 5 (2-18)   
Vancomycin iv (days) 10 (1-105)   
Admission (days) 35 (2-180)   
Gender Frequency (percentage)  
 Male 104 (61%)  
 Female 67 (39%)  
Infection Frequency (percentage)  
 Central venous catheter 79 (46%)  
 Abdominal infection 25 (15%)  
 Implant infection 27 (16%)  
 Endocarditis 10 (6%)  
 Osteomyelitis 6 (4%)  
 Brain abscess or meningitis 5 (3%)  
 Other  
 No infection 
15 (9%) 
4 (2%) 
 
Vancomycine in combination with  Frequency (percentage)  
 No other antibiotic 47 (28%)  
 Broadspectrum penicillin* 65 (38%)  
 Cefalosporine 16 (10%)  
 Meropenem 24 (14%)  
 Ciprofloxacin 8 (5%)  
 Rifampicin 6 (4%)  
 Other** 5 (4%)  
*amoxicillin/clavulanic acid or piperacillin/tazobactam 
** Gentamicine, linezolid and cotrimoxazol 
 
 
 
Pharmacokinetics analysis 
The mean dose (±SD) per 24 hours was 1683 (±759) mg. The mean Vd was 
58 (±30) L, AUC24 was 502 (±97) mg/L×h, CminSS (trough level steady state) was 
13 (±4) mg/L, CmeanSS was 21 (±4) mg/L and CmaxSS (peak level steady state) 
was 49 (±14) mg/L. The mean CLva calculated with MAP Bayesian estimation of 
all patients was 56 (±25) mL/min.  
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Comparison of CLcr estimation formulas  
The mean plasma creatinine was 90 (±58) µmol/L. Five different methods 
of estimation CLcr were compared. Using C&G 53 (31%) patients had a CLcr>125 
mL/min,  76 (44%) patients 60-125 mL/min and 42 (25%) patients ≤60 mL/min. 
Using MDRD-4 39 (23%) patients and MDRD-5 38 (22%) patients had a CLcr ≤60 
mL/min. Albumin was available in only 67 patients, for the MDRD-6 and 27 (40%) 
had a CLcr of ≤60 mL/min. Using CKD-epi 15 (9%) patients had a CLcr >125, 117 
(68%) patients 60-125 and  39 (23%) patients ≤60 mL/min. The best linear 
correlations between CLcr and CLva was R
2
 0.50 with C&G followed by MDRD-5 
R
2 
0.47, CKD-epi R
2
 0.43 and MDRD-4 R
2 
0.43. The MDRD-6 did not improve the 
correlation with CLva (data not shown). 
C&G was used for calculating the CLcr, which was applied in the 3 
prediction methods to predict CLva. Only patients with C&G≤125 mL/min were 
used (n=118), to prevent over estimation of CLcr. However, the results did not 
change significantly when  C&G>125 was set at 125 mL/min (data not shown).  
 
Performance of prediction methods  
The mean estimated CLva of Moise-Broder et al.  was 74 (±25) mL/min, de 
Ryke et al. was 56 (±23) mL/min and Pea et al. was 51 (±15) mL/min and the mean 
CLva calculated with MAP Bayesian Estimation of patients with C&G≤125 mL/min 
(n=118) was 48 (±22) mL/min. The prediction errors were very large for Moise 
Broder -80% and large for De Ryke -28% and Pea -29%. The absolute prediction 
errors were also very large for Moise Broder 83% and large for De Ryke 39% and 
Pea 42% (Figure 1).  
 
Dosing on trough levels 
Pearson correlation (R) and linear correlations (R
2
) between AUC24 and 
trough levels were 0.631 and 0.381, respectively, Figure 2. In Table 3 the 
vancomycin attainment rates (AUC24/MIC ratios≥400) and trough levels are shown. 
Trough levels of 10-15 mg/L have 92% vancomycin attainment rate at MIC=1 
mg/L. With an increasing MIC to >1 mg/L the vancomycin attainment rate dropped 
significantly (Table 3). 
 
Factors influencing the pharmacokinetics of vancomycin  
CLva was correlated to CLcr, creatinine, age, weight, gender and 
neutropenia in the univariable analysis (Table 4). In the multivariable analysis, CLva 
was positively associated with creatinine (B: -0.229, 95%CI: -0.276/-0.183, 
P<0.001), age (B: -0.438 95%CI -0.644/-0.232, P<0.001), neutropenia (B: 12.743, 
95%CI: 2.293/23.293, P=0.017) and weight (B: 0.313, 95%CI 0.134/0.492, 
P=0.001), Table 4. Patients with neutropenia (n=56) had higher CLva, 67 (±26) 
mL/min, compared to patients without neutropenia (n=115), CLva 50 (±22) mL/min 
(P<0.001), while no difference in plasma creatinine was noticed, 80 (±31) and 95 
(±67) µmol/L, respectively (P=0.873). Patients above 70 years had lower CLva than 
patients younger than 70 years (Table 5).  
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Figure 1. Bland Altmann plots for the three prediction methods, Moise-Broder et al., DeRyke et al. and 
Pea et al. 
CLva: vancomycin clearance,  SD: standard deviation. 
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Figure 2. Scatter plot between 24 hour Area Under Curve (AUC24) and trough levels in steady  state.  
 
 
 
 
Table 3. Vancomycin target attainment rates, AUC24/MIC≥400 in patients in our study with a simulated 
MIC=1-2 mg/L. 
 
Trough levels 
(mg/L) 
N 
171 
AUC24 AUC24/MIC≥400 
Median (range) 
(mg×24h/L) 
MIC=1 
(mg/L) 
MIC=1.5 
(mg/L) 
MIC=2 
(mg/L) 
<10 37 428 (351-557) 73% 0% 0% 
10-15 106 502 (343-868) 92% 15% 1% 
15-20 24 587 (405-792) 100% 54% 2% 
>20 4 668 (487-807) 100% 75% 25% 
AUC24: 24 hour area under the curve 
MIC: minimal inhibition level 
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Table 4. Univariable Pearson and multivariable correlation coefficients between CLva and predictors 
used in this study. 
 Univariable Multivariable 
 R P-value B 95% confidence  interval for B P-value 
    Lower bound Upper bound  
CLcr 0.599 <0.001     
Creatinine -0.597 <0.001 -0.229 -0.276 -0.183 <0.001 
Age -0.386 <0.001 -0.438 -0.644 -0.232 <0.001 
Neutropenia 0.322 <0.001 12.743 2.293 23.293 0.017 
Hematologic 
malignancy 
0.300 <0.001 0.400 -10.815 11.615 0.944 
Sepsis 0.170 0.027 -2.496 -9.582 4.582 0.488 
Vd 0.008 0.915 -  - - 
Gender 0.189 0.014 4.290 -1.641 10.641 0.155 
Weight 0.200 0.009 0.313 0.134 0.492 0.001 
CLva: vancomycin clearance 
CLcr: creatinine clearance 
Vd: volume of distribution 
 
 
 
Table 5. CLcr, CLva, Vd, Dose 24 h and AUC24 broken down for age groups and neutropenia. 
Age 
group 
(years)   
N CLcr  
mL/min  
CLva  
mL/min 
Creatinine  
µmol/L 
Vd  
L 
Dose 24h 
mg 
AUC24 
mg×24h/L  
<70  132 123 (±75) 61 (±25) 84 (±46) 55 (±27) 1838(±746) 505 (±98) 
>70  39 65 (±30) 39 (±18) 114 (±85) 69 (±36) 1158(±545) 490 (±94) 
P-
value 
 <0.001 <0.001 0.005 <0.001 <0.001 0.306 
Neutro
-penia    
N CLcr  
mL/min  
CLva 
mL/min 
Creatinine 
µmol/L 
Vd 
L 
Dose 24h 
mg 
AUC24  
mg×24h/L  
No  115 107 (±78) 50 (±22) 95 (±67) 56 (±29) 1521(±727) 499 (±102) 
Yes  56 113 (±57) 67 (±26) 80 (±31) 62 (±32) 2017(±719) 507 (±87) 
P-
value 
 0.142 <0.001 0.873 0.304 <0.001 0.259 
CLva: vancomycin clearance 
CLcr: creatinine clearance 
Vd: volume of distribution 
AUC24: 24 hour area under the curve 
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Discussion 
 
Here, we showed that the CLva prediction methods have a low correlation 
with CLva determined with MAP Bayesian estimation. Moise-Broder et al. had the 
highest mean and absolute prediction error, where DeRyke et al. and Pea et al. had 
lower prediction errors. However, prediction errors were still more than 25%. The 
prediction methods are based on CLcr only and our study showed a linear 
correlation of R
2
 0.50 between the CLcr and CLva. This indicates that CLva 
prediction methods reported in literature are unsuitable for clinical use [1, 4, 5]. 
In our hands, the CLcr estimated with the C&G formula proved to have the 
best correlation with CLva. The estimated CLcr has a good correlation (0.8-0.9) with 
the 24-hour measured creatinine in urine, but is of less value in elderly, critically ill 
patients and when CLcr is higher than 125 mL/min [9]. A 24-hour urine creatinine 
measurement to calculate CLcr might increase the correlation of CLcr with CLva, is 
cumbersome and other co-variates besides CLcr also influence the CLva. In our 
study age and neutropenia also influence the CLva. Higher exposure to vancomycin 
can be expected in elderly patients, as the CLva is lower. On the other hand, lower 
exposure due to augmented CLva can be expected in critically ill patients and in 
neutropenic patients with haematological malignancies [18, 19].  
Another option to reduce TDM is proposed in the IDSA guidelines that 
recommend monitoring only trough plasma levels as the most practical method to 
monitor plasma vancomycin levels [2]. Furthermore, the IDSA guidelines suggest 
increasing the desired trough levels to 15-20 mg/L to obtain an increased target 
attainment of the AUC24/MIC ratios ≥400 with bacterial MIC≤1 mg/L.[2] Although, 
a 100% of the patients in our study with bacterial MIC≤1 mg/L reached an 
AUC24≥400 mg/L×h at trough levels of 15-20 mg/L, the majority (92%) of our 
patients with bacterial MIC≤1 mg/L reached an AUC24≥400 mg/L×h with trough 
levels between 10-15 mg/L. The target of AUC24≥400 mg/L×h cannot be reached 
when bacterial MIC>1 mg/L. Vancomycin induced nephrotoxicity is estimated to be 
twice as  high with trough levels >15 mg/L, increasing from 12% with trough levels 
≤15 mg/L to 25% with trough levels >15 mg/L in the meta-analysis from van Hal et 
al. [20]. Therefore, the majority of patients in our study group have an unnecessary 
increased risk of nephrotoxicity when dosed at high trough levels (15-20 mg/L). 
Furthermore, the trough levels have a poor correlation with AUC24 in our study. This 
is line with Neeley et al., who showed that monitoring of only trough levels is a poor 
surrogate for AUC24 [21]. Although monitoring of vancomycin through levels is 
associated with decreased vancomycin induced nephrotoxicity [2], it does not allow 
accurate calculation of PK parameters (i.e. CLva and AUC24). 
Our study has several limitations. Our study is a real life observational 
study. We assumed the TDM protocol was followed by clinicians, especially the 
timing of peak and trough levels.  Another limitation of our study is that our study 
population differs from the study populations from the prediction methods. Finally, 
we only investigated estimated CLcr, which could weaken our conclusions about the 
prediction methods based on estimated CLcr.   
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Conclusions 
 
The mean and absolute prediction error were  large for all tested prediction 
methods. Therefore, the prediction methods are unsuitable for clinical use. 
Furthermore, dosing based only on trough levels of 15-20 mg/L will bring patients 
needlessly at risk for toxicity and is not sufficient for reaching the efficacy target 
when MIC>1 mg/L. The high variability and unpredictability of CLva and AUC24 
make TDM with MAP Bayesian estimation inevitable for optimal dosing of 
vancomycin.  
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Elderly people are a large growing population of healthcare consumers with 
high numbers of infection and high antimicrobial drug use. To improve 
antimicrobial treatment of infections in elderly patients, it is important to understand 
infections and antimicrobial therapy in elderly patients. Infections occur more often 
in elderly patients. Impaired immunity, which is illustrated by a diminished antibody 
response after vaccination in elderly patients [1-3], make elderly patients more 
vulnerable to infections. The environment of elderly patients, such as living in long 
term care facilities and increased admissions in hospitals, contribute to the risk of 
infection.  
The majority of antimicrobial drugs are prescribed by general practitioners. 
In chapter 2 antimicrobial prescriptions were studied in Dutch general practices. 
The trend from 2000-2009 showed an increase in antimicrobial prescriptions in all 
adult age groups. This was most striking in the very elderly patients; the percentage 
of patients >80 years with at least one antimicrobial prescription per year increased 
from 9% in 2000 to 22% in 2009. Moreover, the patients >80 years were also most 
often prescribed multiple antimicrobial prescriptions per year compared to younger 
age groups. The rise was evident in all antibiotic classes, except for the macrolides. 
Traditionally, the human antimicrobial consumption is low in the Netherlands, but it 
is slowly increasing and might increase further with the ageing population [4-6]. The 
exact cause of this increase is not clear. There are no changes in Dutch general 
practice guidelines for infections. However, the increase in fluoroquinolone 
prescriptions suggests that the guidelines are not always followed. The increase also 
might be explained by an increase in consultations. Unfortunately, we had no access 
to consultation frequency for acute infections in our study. The increase in 
antimicrobial prescriptions is worrisome, as there is a clear relation with 
antimicrobial resistance. Recently, the Dutch Ministry of Health obligated Dutch 
hospitals to assign antimicrobial stewardship teams and programs. However, more 
efficient reduction in antimicrobial use might be feasible in Primary Care. Based on 
our findings, the elderly should be a specific target group.   
When prescribing antimicrobial therapy in elderly patients, there is an 
increased risk of adverse drug events (ADE) or drug-drug interactions. In chapter 2 
co-medication was the most important risk factor for ADE. Elderly patients had 
more co-medication and co-morbidity. In the multivariate analysis co-medication 
was the only independent risk factor of ADE, and not age or co-morbidity. 
Additional risk factors of ADE in elderly patients are increased antimicrobial drug 
blood levels due to altered pharmacokinetics as a result of physiologic changes of 
ageing. Higher age is characterised by a decrease in functional capacity of most 
organs, leading to pharmacokinetic changes in absorption, distribution, protein 
binding and elimination [7]. The most important pharmacokinetic changes that 
influence antimicrobial blood concentrations are a decrease in kidney function and 
changes in volume of distribution (Vd) (chapter 1). Reviews of antimicrobial 
pharmacokinetic studies in elderly patients are scarce and dated [8, 9]. In chapter 1 
the pharmacokinetic studies are reviewed: the decrease in renal clearance is the most 
consistent age related pharmacokinetic change, but no or inconsistent changes in Vd 
are seen.  
 In chapter 3 a High Performance Liquid Chromatography (HPLC) with 
fluorescence detection was developed for measurement of ciprofloxacin and 
validated according to US Food and Drug Administration (FDA) requirements for 
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accuracy, precision, selectivity, sensitivity, reproducibility and stability [10]. In 
chapter 4 this method was used to study ciprofloxacin pharmacokinetics in 
hospitalised patients. An assay based on HPLC with UV detection was used in 
chapter 5 to measure amoxicillin and a fluorescence polarization immunoassay with 
monoclonal antibodies was used in chapters 6 and 7 to measure vancomycin in 
hospitalised patients. Both methods were validated according to FDA requirements. 
Amoxicillin and vancomycin are hydrophilic and renally cleared antimicrobial 
drugs, whereas ciprofloxacin is lipophilic and renally cleared. Expected age 
associated pharmacokinetic changes are a decrease in renal clearance, a decrease in 
Vd of hydrophilic antimicrobial drugs and an increase in Vd of lipophilic 
antimicrobial drugs. Increased blood concentrations of amoxicillin, ciprofloxacin 
and vancomycin were observed in elderly patients, due to a decrease in antimicrobial 
clearance in chapter 4, 5 and 7 (Table 1). No changes or only minor changes were 
seen in Vd for amoxicillin and ciprofloxacin (Table 1).  
 
 
Table 1. Mean (±SD) CL, CLcr, Vd and AUC24 for amoxicillin, ciprofloxacin and vancomycin in patients 
using amoxicillin/clavulanic acid broken down per age group. 
Amoxicillin      
Age group 
[years] 
N CLcr [mL/min] 
mean (SD) 
CLam [L/h]  
mean (SD) 
Vd [L] 
mean (SD) 
AUC24 [mg×h/L] 
mean (SD) 
<70 31 82 (±25) 15 (5) 24 (±5) 312 (128) 
>70 26 55 (±19) 10 (5) 23 (±6) 467 (255) 
P-value  0.007 0.003 0.46 0.006 
Ciprofloxacin      
Age group 
[years] 
N CLcr [mL/min] 
mean (SD) 
CLci [L/h] 
mean (SD) 
Vd [L] 
mean (SD) 
AUC24 [mg×h/L] 
mean (SD) 
<70  41 85 (49) 19 (8) 181 (55) 43 (20) 
>70  39 55 (37) 14 (7) 177 (82) 55 (24) 
P-value   <0.001 0.001 0.48 0.013 
Vancomycin      
Age group 
[years] 
N CLcr [mL/min] 
mean (SD) 
CLva [L/h]  
mean (SD) 
Vd [L] 
mean (SD) 
AUC24 [mg×h/L] 
mean (SD) 
<70  132 123 (±75) 61 (±25) 55 (±27) 505 (±98) 
>70  39 65 (±30) 39 (±18) 69 (±36) 490 (±94) 
P-value  <0.001 <0.001 <0.001 0.306 
CLcr, creatinine clearance 
CLci, ciprofloxacin clearance 
CLam, amoxicillin clearance 
CLva, vancomycin clearance 
Vd, volume of distribution 
AUC24, area under the curve in 24-hours 
 
 
An exception was the Vd of the hydrophilic vancomycin, where an increase of Vd is 
observed, despite a suspected decrease in water volume in elderly patients. This 
increase in Vd is also found by others [11-13]. The Vd is influenced by other patient 
factors, such as serum albumin, fluid infusions and sepsis.  
Dividing the elderly patients further into 70-80 and >80 years, the clearance 
of amoxicillin, ciprofloxacin and vancomycin further decreases with increasing age, 
whereas the Vd for amoxicillin and ciprofloxacin only slightly decreases in the very 
elderly patients (Table 2).  
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Table 2. Mean (±SD) CL, CLcr, Vd and for amoxicillin, ciprofloxacin and vancomycin in patients broken 
down per age group. 
Amoxicillin      
Age group 
[years] 
N CLcr [mL/min] 
mean (SD) 
CLam [L/h/]  
mean (SD) 
Vd [L] 
mean (SD) 
AUC24 [mg×h/L] 
mean (SD) 
<70  31 82 (25) 15 (5) 24 (5) 312 (128) 
70-80  16 65 (15) 12 (5) 24 (6) 383 (170) 
>80  10 39 (11) 8 (4) 22 (7) 602 (317) 
Ciprofloxacin 
Age group 
[years] 
N CLcr [mL/min] 
mean (SD) 
CLci [L/h]  
mean (SD) 
Vd [L] 
mean (SD) 
AUC24 [mg×h/L] 
mean (SD) 
<70  41 85 (49) 19 (8) 181 (55) 43 (20) 
70-80  24 58 (40) 15 (7) 178 (83) 52 (22) 
>80  15 51 (33) 12 (6) 176 (84) 59 (27) 
Vancomycin 
Age group 
[years] 
N CLcr [mL/min] 
mean (SD) 
CLva [L/h]  
mean (SD) 
Vd[L] 
mean (SD) 
AUC24 [mg×h/L] 
mean (SD) 
<70  132 123 (75) 61 (25) 55 (27) 505 (98) 
70-80  31 68 (33) 40 (18) 71 (39) 480 (88) 
>80  8 56 (18) 35 (16) 60 (24) 528 (110) 
CLcr, creatinine clearance 
CL, ciprofloxacin clearance  
Vd, volume of distribution  
AUC24, area under the curve in 24-hours 
 
 
The Pearson correlation coefficients between serum creatinine and clearance of 
amoxicillin, ciprofloxacin and vancomycin were R = -0.529, -0.507 and -0.597, 
respectively, and between estimated CLcr and clearance of amoxicillin, 
ciprofloxacin and vancomycin were R = 0.843, 0.692 and 0.599, respectively (Table 
3). This means that the serum creatinine or the estimated CLcr only partly predicts 
the clearance of amoxicillin, ciprofloxacin and vancomycin (51-60%) and other 
factors influence the antimicrobial clearance. In the multivariable analysis age and 
creatinine were independently associated with the clearance of amoxicillin, 
ciprofloxacin and vancomycin (Table 3). Therefore, monitoring serum creatinine 
and estimation of CLcr with an algorithm from serum creatinine is necessary in 
elderly patients, but because of moderate correlation with antimicrobial clearance 
the value is limited in antimicrobial dosing. Indeed, in Chapter 7 prediction 
methods based on CLcr to predict the vancomycin clearance, showed large 
prediction errors and were unsuitable for patient care. Different methods to estimate 
the CLcr, i.e. Cockcroft-Gault formula, several Modification of Diet in Renal 
Disease and Chronic Kidney Disease Epidemiology Collaboration formula were 
compared, but all methods showed a correlation of R
2
 of 0.50 with the measured 
clearance of vancomycin. More precise determination of kidney function, such as 
measurement of creatinine in urine, inulin, iohexol, or 
125
I-Iothalamate, or still better 
therapeutic drug monitoring (TDM) of the antimicrobial drugs should be considered 
in elderly patients. Other factors influence the clearance of antimicrobial drugs; e.g. 
age independently decreases the amoxicillin, ciprofloxacin and vancomycin 
clearance (Table 3). Additionally, in chapter 6 we showed that neutropenia 
independently augments the vancomycin clearance. Similar augmented clearance is 
observed in Intensive Care Unit patients [14-16]. Most likely augmented clearance 
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also influences other renally cleared antibiotics [17, 18]. More in depth studies are 
needed to understand the aetiology, duration and consequences of augmented 
clearance of antimicrobial drugs.  
 
 
Table 3. Univariable Pearson correlation coefficients and multivariable linear regression analysis of 
amoxicillin, ciprofloxacin and vancomycin. 
Amoxicillin Univariable CLam Multivariable CLam 
 R P-value Beta 95% CI  P-value 
    Lower Upper  
Age -0.503 <0.001 -0.141 -0.188 -0.094 <0.001 
Creatinine -0.529 <0.001 -0.069 -0.090 -0.049 <0.001 
Gender -0.111 0.409     
Weight 0.396 0.002 0.363 -0.024 0.064 0.363 
Vd 0.623 <0.001 0.506 0.352 0.659 <0.001 
Ciprofloxacin Univariable CLci Multivariable CLci 
 R P-value Beta 95% CI  P-value 
    Lower Upper  
Age -0.377 0.001 -0.144 -0.223 -0.064 0.001 
Creatinine -0.507 <0.001 -0.030 -0.040 -0.019 <0.001 
Gender -0.199 0.076     
Weight 0.154 0.173     
Vd 0.334 0.002 0.036 0.017 0.055 <0.001 
Vancomycin Univariable CLva Multivariable CLva 
 R P-value Beta 95% CI  P-value 
    Lower Upper  
Age -0.386 <0.001 -0.405 -0.602 -0.208 <0.001 
Creatinine -0.597 <0.001 -0.228 -0.275 -0.181 <0.001 
Gender 0.189 0.014 4.121 -1.78 10.08 0.169 
Weight 0.200 0.009 0.334 0.160 0.509 <0.001 
Vd 0.008 0.915     
Neutropenia 0.322 <0.001 13.169 2.75 23.59 0.014 
Hemato- 
oncology 
0.300 <0.001 0.849 -10.34 12.04 0.881 
Sepsis 0.170 0.027 -2.839 -9.90 4.22 0.428 
CLci, ciprofloxacin clearance 
CLam, amoxicillin clearance 
CLva, vancomycin clearance 
Vd, volume of distribution  
 
 
In chapter 4 and 5, we showed that pharmacodynamic (PD) targets are not 
reached with standard dosing regimens in a considerable part of the hospitalised 
patients, both young and elderly, which is in line with other studies [19-21]. In 
Chapter 4, 21% and 75% of the patients that received the standard dose of 
ciprofloxacin did not reach the PD-target of AUC24/MIC>125 with bacterial 
minimal inhibition concentration (MIC) of 0.25 and 0.5 mg/L, resp. The percentages 
of elderly patients that did not reach the PD-target were, 18% and 59% with 
bacterial MIC of 0.25 and 0.5 mg/L, resp. In Chapter 5, 7% and 35% of the total 
amount of patients that received the standard dose of amoxicillin/clavulanic acid did 
not reach the PD target of 40%T>MIC with bacterial MIC of 4 and 8 mg/L, resp. 
The percentages of elderly patients (>70 years) that did not reach the PD-target were 
0% and 13% with bacterial MIC of 4 and 8 mg/L, respectively. Ciprofloxacin and 
amoxicillin are underdosed in adult patients and this dose is more appropriate for 
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elderly patients. Vancomycin is dosed with TDM and most patients reached an 
AUC24≥400 mg×h/L, where the PD-target is reached for MIC=1 mg/L. However, 
elderly patients needed lower vancomycin mean 24-hour dose (±SD) than younger 
patients, i.e. patients >70 years received a mean of 1158 (±545) mg of vancomycin 
per 24 hours and patients <70 years 1838 (±746) mg.  Dosing on the PD-target of 
vancomycin AUC24/MIC≥400 is not advisable with MIC≥2 mg/L due to toxicity 
[22] (chapter 7). In general our hospitalised patients did not reach the PD-targets 
with the standard antimicrobial dose. Increasing the standard dose for ciprofloxacin 
iv to 400 mg three times daily decreases the percentage of patients that did not reach 
the PD-target to 1% and 37%, for MIC 0.25 and 0.50 mg/L, resp. (chapter 4) and 
increasing the amoxicillin iv dose to 1000 mg 6 times daily decreases the percentage 
to 0% and 5% for MIC 4 and  8 mg/L, respectively (chapter 5). A ciprofloxacin 
dose of 400 mg 3 times daily is sufficient for most elderly patients, because the 
percentage of patients that did not reach the PD-target is 0% and 15% for bacterial 
MIC of 0.25 mg/L and 0.50 mg/L, respectively. The standard dose of amoxicillin is 
appropriate for all elderly patients in our study group. 
In conclusion, age and serum creatinine are independent factors of the 
clearance of amoxicillin, ciprofloxacin and vancomycin. This results in increased 
amoxicillin, ciprofloxacin and vancomycin blood concentrations in elderly patients. 
However, the decrease in antimicrobial clearance is difficult to predict with serum 
creatinine and estimated CLcr, as the correlation of serum creatinine and estimated 
CLcr with antimicrobial clearance is only moderate and a high interindividual 
difference in decline of glomular filtration rate is seen with ageing [28]. The Vd of 
both hydrophilic and lipophilic renally cleared antimicrobial drugs does not change 
consistently. Therefore, it is not possible to adjust antimicrobial dosing according to 
changes in Vd with ageing. Especially in elderly patients, TDM is necessary to 
ensure efficacy and prevent toxic concentrations for antimicrobial drugs with small 
therapeutic window, such as aminoglycosides, vancomycin and linezolid. 
Additionally, in elderly patients TDM might prevent ADEs in antimicrobial drugs 
close to high toxic levels. In specific groups of patients with risk of underdosing due 
to augmented clearance, such as patients admitted at the ICU and in neutropenic 
patients, TDM might be worthwhile to reach PD targets and improve outcome.   
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Future perspectives 
 
Improving antimicrobial therapy in the growing population of elderly patients 
will require more studies, both on the exact dose of antimicrobial drugs and on 
targeted blood levels. Studies that follow trends in antimicrobial prescriptions over 
time should be continued, especially in elderly patients. Studies analysing drug 
prescriptions, factors for increasing antimicrobial drug use in association with 
diagnosis and treatment are needed both in hospital setting and in primary care.  
To fill the gap in pharmacokinetic studies in elderly patients, antimicrobial 
pharmacokinetic population studies are needed. These studies should be done in 
well-defined age groups with specific attention to patients at the end of the life 
spectrum, i.e. very elderly patients (>80 year) and frail elderly patients. Age related 
pharmacokinetic changes might be more clear at the end of the life spectrum. FDA 
approved measuring methods of antimicrobial blood levels should be used. 
Our suggested dose adjustments of  amoxicillin/clavulanic acid 1000/200 mg iv 
6 times daily and ciprofloxacin 400 mg iv three times daily to attain PD-targets, 
should be validated in prospective studies. In depth studies of mechanism, duration 
and other covariates of augmented antimicrobial drug clearance in neutropenic and 
ICU-patients should be combined with preferably not burdensome and more precise 
measurement of kidney function. The augmented antimicrobial drug clearance 
together with other suggested covariates, such as co-medication, sepsis, age and 
genetic factors should be followed over time to get more insight in duration and  
mechanism of augmented antimicrobial drug clearance. 
A standard antimicrobial dose might be sufficient for the majority of patients, 
but does not fit all patients. This thesis shows that elderly patients generally need 
lower dose than younger patients to reach PD-targets of antimicrobial drugs. 
Especially, for antimicrobial drugs with small therapeutic range more individual 
dosing of elderly patients with TDM will be necessary to safely increase the dose to 
improve clinical outcome and keep toxicity low. It might decrease antimicrobial 
drug resistance. Individual dosing of antimicrobial drugs which takes into account 
the MIC of an antimicrobial drug for the infecting micro-organism and TDM or a 
dosing regimen that is likely to obtain the PD-targets should also be a strategy in 
antibiotic stewardship programs. 
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Het aantal ouderen en het percentage ouderen ten opzichte van de hele 
bevolking neemt gestaag toe in ontwikkelde landen. Dit komt aan de ene kant 
doordat de levensverwachting er toeneemt en aan de andere kant het geboortecijfer 
er afneemt. In hoofdstuk 1 worden classificaties besproken van de oudere patiënt. 
De meest gebruikte grenzen voor ouderen zijn 65 en 70 jaar. Voor hoogbejaarden 
wordt een grens van 80 jaar het meest gebruikt, maar elke grens is artificieel. 
Bovendien bestaat er een grote variatie in kalenderleeftijd en biologische leeftijd van 
persoon tot persoon. In hoofdstuk 1 wordt een overzicht gegeven van 
farmacokinetische veranderingen tijdens het verouderingsproces. Ook wordt er een 
overzicht gegeven van de antimicrobiële farmacokinetische studies bij oudere 
vrijwilligers en oudere patiënten. Bij ouderen treedt een vermindering op van de 
functionele capaciteit van alle organen. Dit leidt tot veranderingen in absorptie, 
eiwitbinding en eliminatie van antimicrobiële middelen bij oudere patiënten. 
Volgens farmacokinetische reviews van antimicrobiële therapie bij oudere patiënten 
uit 1987 en 1989 lijken de belangrijkste farmacokinetische veranderingen: 1. een 
verandering in het verdelingsvolume en 2. een vermindering van de nierfunctie te 
zijn. Het verdelingsvolume van ouderen verandert door een afname van het  
lichaamswater en een toename van het lichaamsvet. Dit zou tot gevolgen kunnen 
leiden voor water- (hydrofiele) en vetoplosbare (lipofiele) antimicrobiële middelen. 
Echter, het overzicht van antimicrobiële farmacokinetische studies bij oudere 
vrijwilligers en patiënten in hoofdstuk 1 laat zien dat de veranderingen in het 
verdelingsvolume niet eenduidig zijn. De vermindering van de nierfunctie lijkt 
daarentegen de belangrijkste en meest consistente farmacokinetische verandering bij 
oudere patiënten. Hierdoor kunnen de concentraties van renaal geklaarde 
antimicrobiële middelen onbedoeld verhoogd zijn bij oudere patiënten. Het gevaar 
bestaat dat er bijwerkingen ten gevolge van toxiciteit kunnen optreden. Wel moet 
een kanttekening gemaakt worden dat er betrekkelijk weinig studies zijn verricht 
naar de farmacokinetiek van antimicrobiële middelen specifiek in oudere patiënten. 
Meer onderzoek naar de farmacokinetiek van antimicrobiële middelen bij oudere 
patiënten is daarom belangrijk. 
Het merendeel van alle antimicrobiële middelen wordt door de huisarts 
voorgeschreven (80%).  In hoofdstuk 2 worden dan ook de antimicrobiële 
voorschriften bestudeerd in huisartspraktijken van het Registratie Netwerk 
Huisartsen (RNH) in Limburg. Tussen 2000-2009 zijn 658.940 patiëntjaren 
onderzocht. Over deze 10 jaar krijgt 11,5% van de patiënten tenminste één keer een 
antibioticum voorschrift per jaar. Over deze 10 jaar wordt een duidelijke toename 
waargenomen van het aantal antimicrobiële voorschriften in alle volwassen 
leeftijdsgroepen. De grootste stijging wordt bij de aller oudsten gezien, van de 
leeftijdsgroep ouder dan 80 jaar stijgt het aantal patiënten dat tenminste één 
antimicrobieel voorschrift per jaar krijgt van 9% in  2000 naar 22% in 2009. Ook 
krijgen mensen ouder dan 80 jaar vaker meer dan één antimicrobieel middel per jaar 
voorgeschreven. Deze stijging geldt voor alle antimicrobiële middelen, behalve voor 
de macroliden. Hoewel er geen duidelijke oorzaak van deze stijging wordt 
gevonden, baart deze ontwikkeling wel zorgen, vanwege de duidelijke relatie tussen 
het antibiotica gebruik en het ontstaan van antimicrobiële resistentie. Daarnaast is in 
hoofdstuk 2 gevonden dat oudere patiënten vaker bijwerkingen hebben van 
antimicrobiële middelen. In de univariate analyse zijn co-medicatie, leeftijd en 
chronische ziekten geassocieerd met het ontwikkelen van bijwerkingen. In de 
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multivariate analyse is alleen co-medicatie nog geassocieerd met het ontwikkelen 
van bijwerkingen. Oudere patiënten hebben uiteraard veel meer co-medicatie dan 
jongere patiënten.  
In hoofdstuk 3 is een high performance liquid chromatography (HPLC) 
methode met fluorescentie detectie ontwikkeld om de concentratie van  
ciprofloxacine in het bloed nauwkeurig te bepalen. Deze methode is volgens de 
Amerikaanse richtlijnen voor voedsel en medicijn registratie (Food and Drug 
Administration, FDA) voor accuraatheid, precisie, selectiviteit, sensitiviteit, 
reproduceerbaarheid en stabiliteit gevalideerd. In hoofdstuk 4 is deze methode 
gebruikt om ciprofloxacine concentraties in het bloed te bepalen van 
ziekenhuispatiënten. Een bestaande HPLC met ultraviolet licht detectie is in 
hoofdstuk 5 gebruikt om amoxicilline concentraties in het bloed van patiënten te 
bepalen. In hoofdstuk 6 en 7 is een fluorescentie polarisatie immunoassay (FPIA) 
met monoclonale antilichamen toegepast om vancomycine concentraties in het bloed 
te meten. Alle methoden zijn volgens FDA richtlijnen gevalideerd.  
Hoofdstuk 4 en 5 laten zien dat de farmacodynamische targets met de standaard 
doseringen van ciprofloxacine en amoxicilline/clavulaanzuur in een belangrijk 
gedeelte van de patiënten niet gehaald worden. In hoofdstuk 4 haalt 21% van de 
patiënten de ciprofloxacine target niet als de minimum inhibitory concentration 
(MIC) van de bacterie, die de infectie veroorzaakt 0.25 mg/L is.  Dit percentage 
loopt op naar 75% als de MIC van de bacterie 0.50 mg/L is. Het percentage ouderen 
(>70 jaar), die de ciprofloxacine target niet haalt ligt lager, namelijk 18% bij een 
MIC van 0.25 mg/L en 59% bij een MIC van 0.50 mg/L. Als de MIC van de bacterie 
(Enterobacteriaceae spp.), die de infectie veroorzaakt, tussen 0.5-1 mg/L ligt wordt 
deze als intermediair beschouwd. Het is dan onzeker of het antimicrobiële middel 
een therapeutisch effect zal hebben. In hoofdstuk 5 haalt respectievelijk 7%  van de 
patiënten de amoxicilline target niet als de MIC van de bacterie, die de infectie 
veroorzaakt, 4 mg/L is. Dit percentage loopt op naar 35% als de MIC van de bacterie 
8 mg/L is. Bij amoxicilline halen alle ouderen (>70 jaar) de  amoxicilline target bij 
een MIC van 4 mg/L en  slechts een klein deel van de ouderen haalt de target niet 
(13%) bij een MIC van 8 mg/L. Als de MIC van de bacterie (Enterobacteriaceae 
spp.), die de infectie veroorzaakt, groter dan 8 mg/L is wordt deze als resistent 
beschouwd. Amoxicilline kan dan niet meer als therapie gegeven worden. Uit deze 
resultaten kan worden afgeleid dat de concentratie van amoxicilline en 
ciprofloxacine bij ouderen hoger zijn dan bij jongere patiënten. Dit wordt 
veroorzaakt door een verminderde klaring van zowel amoxicilline als 
ciprofloxacine, want het verdelingsvolume van amoxicilline en ciprofloxacine is 
gelijk bij oudere en jongere patiënten.  Een hogere amoxicilline dosering van 6 maal 
daags 1000 mg iv is vooral belangrijk bij jongere patiënten. De meeste oudere 
patiënten hebben voldoende aan 4 maal daags 1000 mg iv. Een hogere standaard 
ciprofloxacine dosering van 3 maal daags 400 mg iv bleek volgens onze simulatie 
voldoende voor vrijwel alle oudere patiënten én voor de meeste jongere patiënten 
voldoende.  
In hoofdstuk 6 en 7 is vancomycine bestudeerd. Vancomycine wordt 
routinematig gedoseerd op geleide van vancomycine spiegels in het bloed; 
therapeutic drug monitoring (TDM). Bij gebruik van TDM halen vrijwel alle 
patiënten de farmacodynamische target en zijn dus goed gedoseerd. Het bleek dat 
oudere patiënten (>70 jaar) hiervoor gemiddeld een veel lagere vancomycine dosis 
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nodig hebben, namelijk 1158 mg/24 uur dan jongere patiënten (<70 jaar), 1838 
mg/24 uur. Hoofdstuk 6 laat ook zien dat patiënten met een neutropenie een snellere 
klaring van vancomycine hebben en een hogere dosering nodig hebben om de 
farmacodynamische target te halen. Het lijkt erop dat deze snellere klaring reversibel 
is onze kleine groep van patiënten, die een tweede episode van vancomycine 
toegediend hebben kregen tijdens een niet-neutropene fase. Het mechanisme van 
deze versnelde klaring is nog niet opgehelderd. Waarschijnlijk spelen meerdere 
factoren een hierbij een rol. 
 In hoofdstuk 7 zijn methoden om vancomycine klaring te voorspellen op basis 
van creatinine klaring onderzocht. De onderzochte methoden laten echter grote 
variatie zien en zijn daarom niet geschikt om te gebruiken bij patiënten. Het meten 
van vancomycine spiegels blijft daarom noodzakelijk om effectief te doseren ten 
einde de kans op bijwerkingen zo klein mogelijk te houden.  
Van de onderzochte co-variabelen hebben enkele invloed op de klaring van 
amoxicilline, ciprofloxacine en vancomycine. In hoofdstuk 8 laat de multivariabele 
analyse zien dat leeftijd en serum creatinine belangrijke factoren zijn, die 
onafhankelijk van elkaar van invloed zijn op de klaring van amoxicilline, 
ciprofloxacine en vancomycine. Dit resulteert in hogere concentraties van 
amoxicilline, ciprofloxacine en vancomycine in serum van oudere patiënten in 
vergelijking met jongere patiënten. Het meten van creatinine in het bloed om de 
creatinine klaring te schatten geeft een indicatie van de nierfunctie van ouderen, 
maar is van beperkte waarde in het doseren van antimicrobiële middelen bij ouderen 
vanwege een matige correlatie met de antimicrobiële klaring. Bovendien zijn er 
grote individuele verschillen in de daling van de nierfunctie van oudere patiënten. 
Aanpassingen van de antimicrobiële dosis bij oudere patiënten op basis van een 
verminderde  nierfunctie wordt hierdoor bemoeilijkt. Wellicht dat in de toekomst 
ontwikkelde betere bepalingen van de nierfunctie in oudere patiënten wel 
aanpassingen in dosering mogelijk maken. In hoofdstuk 8 worden geen verschillen 
in het verdelingsvolume van amoxicilline, ciprofloxacine en vancomycine tussen 
oudere en jongere patiënten gezien. Het lijkt daarom  niet nodig om doseringen aan 
te passen op de te verwachte veranderingen in het verdelingsvolume bij oudere 
patiënten. Bij renaal geklaarde antimicrobiële middelen met kleine therapeutische 
breedte, zoals aminoglycoside, vancomycine en linezolid, is het meten van 
antimicrobiële spiegels met behulp van TDM de beste optie om optimaal te doseren 
bij oudere patiënten. Aanpassing van de dosering van renaal geklaarde 
antimicrobiële middelen met grote therapeutische breedte, zoals amoxicilline, is bij 
oudere patiënten minder noodzakelijk. Concluderend behoeven oudere patiënten, net 
zoals jongere patiënten, andere doseringen, waarbij de alleroudsten net zoals de 
allerjongsten het meest afwijken van het gemiddelde.  
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Relevance for society and economy 
 
The population in the developed countries is ageing. In 2012 the European 
life expectancy at birth was 83 years for women and 78 years for men. It is 
expected that the life expectancy will increase further. However, not only in the 
developed countries, but also in the developing countries life expectancy is 
increasing. The United Nations predicts that the global life expectancy will reach 
76 years in 2045-2050 and 82 years in 2095-2100 [1]. Another trend in the 
developed countries is a decreasing birth rate, e.g. in the Netherlands the 
birthrate in 1950 was 23‰ (= 23 per 1000 inhabitants) and in 2013 it decreased 
to 10‰ [2], resulting in a relatively larger elderly proportion of the population. 
As a result of the ageing population many governments are extending the 
retirement age to 67 years. Further extending of the retirement age can be 
expected with increasing life expectancy. A substantial proportion of the 
working population will consist of elderly people. Elderly people have more co-
morbidities and experience more infections. Elderly people use more 
antimicrobial agents than younger people. Improving antimicrobial therapy for 
elderly patients will decrease morbidity and mortality of infections in elderly 
patients. This is important for the elderly patient and his or her family, but it will 
also keep the sickness absence in the working elderly population as short as 
possible. Furthermore, correct dosing might lead to a decrease of antimicrobial 
resistance. Increasing antimicrobial resistance is a worldwide problem. 
Antimicrobial stewardship programs are an internationally recognized method to 
control antimicrobial resistance. Antimicrobial stewardship programs focus on 
correct antimicrobial therapy, recognizing and controlling antimicrobial 
resistance. The Dutch Ministry of Health supports these programs. They 
obligated all Dutch hospitals to have working antimicrobial stewardship 
programs and antibiotic teams in every Dutch hospital by the end of 2015.  
The goal of this thesis was to study the use and the pharmacokinetics of 
antimicrobial drugs in elderly and very elderly patients.  The ultimate goal by 
improving the antimicrobial therapy in elderly patients is to improve the health 
of elderly patients. 
 
 
Target groups  
 
       Many  doctors, such as general practitioners, medical microbiologists and 
infectious disease specialists, ICU doctors, internal medicine doctors and 
surgeons, will regularly prescribe antimicrobial therapy to elderly patients. 
Studies about the use of antimicrobial therapy and antimicrobial 
pharmacokinetics will improve the knowledge of  these doctors, who are treating 
infections in elderly patients. These studies are also important for the elderly 
patients themselves and for their families. These studies might also be useful for 
policy makers of the Ministry of Health and Economics, directories of Hospitals 
and Nursing homes and insurance companies.  
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Activities, innovations, planning and realization 
 
 
Traditionally the antimicrobial use in the Netherlands has been low. There 
are many activities to keep this antimicrobial use low and to improve 
antimicrobial therapy. However, focus on elderly patients has been lacking, 
while  the necessity and the importance of this increasing age group is 
acknowledged. This thesis adds more insight in antimicrobial treatment in 
elderly patients and shows that the elderly patients are a large growing group that 
consume high quantities of antimicrobial drugs.  This thesis indicates that focus 
on elderly patients is warranted.  
The antimicrobial stewardship programs and teams have just recently started 
and have to evolve to reduce antimicrobial consumption, to ensure correct 
antimicrobial therapy and to control antimicrobial resistance in the future. The 
antimicrobial stewardship teams consist of medical microbiologists, infectious 
disease specialists and clinical pharmacists that focuses on the hospitals. 
Strategies have to be developed that focus on patient groups that consume the 
highest quantity of antimicrobial drugs, i.e. the elderly patients. Additionally, 
general practioners and internist geriatricians might have to be included in these 
teams and programs. 
The Dutch Working Party on Antibiotic Policy (SWAB) monitors 
antimicrobial resistance in hospitals and in the community, but might have to  
extend this surveillance to nursing homes. Recently, the yearly SWAB report on 
human antimicrobial use and surveillance of antimicrobial resistance (Nethmap) 
included in 2014 a more complete chapter of antimicrobial use in Primary Care 
and Dutch hospitals [3]. Unfortunately, there was no focus on elderly patients or 
on other high antimicrobial  drugs consuming patient groups.  
Finally, more advertisement in more easily accessible programs can also be 
used to address the importance of antimicrobial therapy in elderly patients. For 
instance, the European Antibiotic Awareness Day, which is an initiative of the 
European Centre for Disease Prevention and Control (ECDC), is held yearly to 
improve awareness of antibiotics. This day could focus on high consuming 
patient groups, such as the elderly patients.   
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Epiloog 
 
 
Mijn promotietraject is begonnen met een open sollicitatie in 2008 bij de 
afdeling Medische Microbiologie van het Academisch Ziekenhuis in Maastricht 
(AZM). Dit betrof een open sollicitatie omdat mijn vriendin aangenomen was 
voor de opleiding tot anesthesioloog, ook in het AZM. 
Graag wil ik mijn promotoren Annelies Verbon, Cathrien Bruggeman, 
Christian Hoebe en mijn co-promotor Leo Stolk bedanken voor deze 
mogelijkheid en het vertrouwen dat zij in mij gesteld hebben. Annelies Verbon 
en Cathrien Bruggeman hebben mij in korte tijd op meerdere onderzoekssporen 
gezet waarbij de nadruk op ouderen lag. Het begon met onderzoek bij patiënten 
met COPD in de 1
e
 lijn. Later volgde onderzoek naar associaties tussen 
herpesvirussen en hart- en vaatziekten, diabetes mellitus, frailty en mortaliteit in 
een psychogeriatrisch ouderen cohort van Evelien Pijpers in samenwerking met 
Valère Goossens en onderzoek naar respiratoire virussen binnen het MUMC in 
samenwerking met Ruud Deurenberg, Inge van Loo en Petra Wolffs. 
Antibiotica voorschriften in de eerste lijn in samenwerking met Christian 
Hoebe, Nicole Dukers en Jochen Cals en antibioticaspiegels bij ouderen in het 
ziekenhuis in samenwerking met Leo Stolk en Cees Neef. Uiteindelijk heeft dit 
proefschrift vorm gekregen door de laatst genoemde onderwerpen.  
Het eerste deel van dit onderzoek is tot stand gekomen door een 
samenwerking tussen het RNH, de GGD in Heerlen en de Medische 
Microbiologie. In samenwerking met Alphons Schroten, Marjan van den Akker, 
Jochen Cals en professor Metsemakers vanuit het RNH, Christian Hoebe en 
Nicole Dukers vanuit de GGD en Annelies Verbon en Cathrien Bruggeman 
vanuit de Medische Microbiologie hebben we antibiotica voorschriften in de 
RNH database kunnen bestuderen over een periode van 10 jaar. 
Het leeuwendeel van dit boek is verricht in samenwerking met de apotheek. 
Alvorens we verschillende antibiotica spiegels hebben kunnen meten moest er 
bloed van patiënten verzameld worden. In samenwerking met Otto Bekers en de 
analisten van de Klinische Chemie werden overgebleven bloedmonsters 
gebruikt van patiënten, die ook antibiotica kregen toegediend. De secretaresses 
van  A4, B4 en B5 markeerden de aanvragen voor de Klinische Chemie, zodat 
de medewerkers van de prikdienst en de verpleegkundigen wisten bij welke 
bloedafnames de afnametijden genoteerd moesten worden. Het restmateriaal en 
de afnametijden van deze bloedmonsters kon ik na gebruik terugzoeken. 
Hiervoor was ook de medewerking nodig van de hoofdzusters van deze 
afdelingen; Jacqueline Scheijen (A4), Marjo Kleijnen (B4) en Gertie Brepoels 
(B5) en afdelingshoofden van de Interne Geneeskunde en Heelkunde.  
Ik wil alle analisten van het labarotorium van de apotheek, en Jeroen 
Welzen en Jacques van der Heyden in het bijzonder, bedanken voor de prettige 
en leerzame samenwerking op dit uitstekende lab. Altijd heb ik de nodige hulp 
gekregen bij de HLPC bepalingen, waardoor ik rustig heb kunnen doorwerken 
aan alle bepalingen. Ook hebben twee WESP studenten, Inez Widow en Pauline 
Vinken, geholpen bij de HPLC bepalingen en analyses. De inbreng van Leo 
Stolk is heel belangrijk geweest, zowel bij het opzetten van de HPLC’s, bij het 
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valideren van deze HPLC’s en bij de pharmacokinetiek met behulp van  
MW/Pharm. Thomas Havenith en Sander Croes hebben veel werk verricht bij 
respectievelijk het amoxicilline en het vancomycine onderzoek. Ook Thomas en 
Sander hebben mijn pharmacokinetische kennis vergroot. Cees Neef wil ik ook 
hartelijk bedanken voor zijn hulp en medewerking.  
Het analyseren van de data en het schrijven van de artikelen moest al snel 
telefonisch en vooral per email gebeuren. Annelies Verbon heeft mij in korte 
tijd op het juiste spoor gezet, voordat zij in 2009 vertrok naar het Erasmus MC 
in Rotterdam. In 2010, precies 2 jaar na de start van mijn promotieonderzoek 
ben ik ook begonnen aan de opleiding tot Medisch Microbioloog. Niet veel later 
ging Cathrien Bruggeman met een welverdiend pensioen en uiteindelijk is ook 
Leo Stolk met een welverdiend pensioen gegaan. Toch hebben deze 
veranderingen het analyseren en het schrijven van de artikelen niet belemmerd. 
Integendeel, Annelies en Leo reageerden altijd buitengewoon scherp en snel op 
al mijn emails. Voor mij heeft dit uitstekend gewerkt. Ik heb altijd rustig 
kunnen door werken aan mijn promotieonderzoek. Het was gewoon een goed 
promotieteam, waarbij ook Cathrien, Christian, Nicole, Jochen, Sander, Thomas 
en Cees altijd adequaat en snel reageerden bij het analyseren en schrijven van 
de artikelen.  
Het is helaas onmogelijk om iedereen te benoemen en te bedanken, die een 
bijdrage hebben geleverd aan het tot stand komen van dit boek. Desalniettemin, 
wil ik iedereen, die een bijdrage heeft geleverd bedanken voor alle hulp, 
informatie en adviezen. Deze zijn allemaal dankbaar in ontvangst genomen. 
Niet in de laatste plaats wil ik ook alle patiënten bedanken, die deelgenomen 
hebben aan de RNH-database en alle patiënten in het MUMC, die geen bezwaar 
hebben gemaakt tegen anoniem gebruik van reeds verzamelde gegevens en van 
reeds afgenomen lichaamsmaterialen voor wetenschappelijk onderzoek. Een 
speciaal en niet te onderschatte dankwoord moet ik richten aan de technische 
dienst, zij hebben bij een incident een groot deel van mijn onderzoek gered. De 
verouderde -80 researchdiepvries van de apotheek gevuld met de -met bloed, 
zweet en tranen verzamelde- monsters gaf midden in de nacht de pijp aan 
Maarten. De technische dienst merkte dit heel snel op en zij hebben ‘s nachts 
alle monsters verplaatst naar een splinternieuwe reserve -80 diepvries.  
Tot slot wil ik het secretariaat van de Medische Microbiologie bedanken, in 
het bijzonder Angèle Eerens, die het laatste stukje van mijn promotie in goede 
banen heeft geleid. 
De laatste regels van deze epiloog zijn natuurlijk voor mijn lief en mijn vier 
lieve dochters, Charley, Yanna, Faye en Imme. “Never a dull moment”, zoals 
Annelies het verwoordde, en dat klopt wel. Vervelen heb ik me de afgelopen 
jaren niet gedaan! Dit boek draag ik dan ook aan jullie op, Audrey en CYFI.  
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hij met de opleiding tot arts-microbioloog  in hetzelfde  MUMC met als opleider 
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